A 55-year-old woman comes to the emergency department because of epigastric pain, sweating, and breathlessness for 45 minutes. She has hypertension treated with hydrochlorothiazide. She has smoked 1 pack of cigarettes daily for the past 30 years and drinks 1 glass of wine daily. Her pulse is 105/min and blood pressure is 100/70 mm Hg. Arterial blood gas analysis on room air shows: pH 7.49 pCO2 32 mm Hg pO2 57 mm Hg Which of the following is the most likely cause of hypoxemia in this patient?
A 34-year-old woman, gravida 2, para 2, is admitted to the hospital because of shortness of breath and fatigue 2 weeks after delivery of a full-term female newborn. She has no history of major medical illness. Cardiac examination on admission shows an S3 gallop and a grade 2/6 holosystolic murmur heard best at the apex. Treatment is initiated with intravenous furosemide and captopril. Her symptoms resolve, and 3 weeks later, cardiac examination shows no murmur. Which of the following is the most likely explanation for the initial auscultation findings?
A 25-year-old man comes to the emergency department because of a 1-week-history of progressively worsening dyspnea and intermittent chest pain that increases on inspiration. He had an upper respiratory tract infection 2 weeks ago. His pulse is 115/min and blood pressure is 100/65 mm Hg. Examination shows inspiratory crackles bilaterally. His serum troponin I is 0.21 ng/mL (N < 0.1). An x-ray of the chest shows an enlarged cardiac silhouette and prominent vascular markings in both lung fields; costophrenic angles are blunted. A rhythm strip shows inverted T waves. Which of the following additional findings is most likely in this patient's condition?
A 65-year-old man comes to the physician for a follow-up examination. He has chronic obstructive pulmonary disease and was recently discharged from the hospital for an exacerbation. His cough and chills have since improved, but his mobility is still severely limited by dyspnea and fatigue. He smoked 2 packs of cigarettes daily for 30 years, but quit 5 years ago. His medications include inhaled daily budesonide, formoterol, and tiotropium bromide plus ipratropium/albuterol as needed. Pulmonary function testing shows an FEV1 of 27% of predicted. Resting oxygen saturation ranges from 84–88%. Which of the following steps in management is most likely to increase the chance of survival in this patient?
A 60-year-old Caucasian man comes to the physician because of progressive fatigue, shortness of breath, and leg swelling for the past 4 months. He has to pause several times when climbing one flight of stairs. For the past 10 years, he has had joint pain in his hands, wrists, and knees. He has diabetes mellitus and hypertension controlled with daily insulin injections and a strict low-calorie, low-sodium diet. He takes ibuprofen as needed for his joint pain. His wife says that he snores at night. He drinks two to three beers daily. He has smoked half a pack of cigarettes daily for the past 40 years. He went camping in northern New York one week ago. His vital signs are within normal limits. Physical examination shows jugular venous distention, pitting edema around the ankles, and tanned skin. Crackles are heard at both lung bases. An S3 is heard at the apex. The liver is palpated 2 to 3 cm below the right costal margin. His skin appears dark brown. An ECG shows a left bundle branch block. Echocardiography shows left atrial and ventricular enlargement, reduced left ventricular ejection fraction, and mild mitral regurgitation. Which of the following is most likely to have prevented this patient's condition?
A 63-year-old man comes to the physician because of a 3-week history of fatigue and shortness of breath. Physical examination shows diminished breath sounds at the right lung base. An x-ray of the chest shows blunting of the right costophrenic angle. Thoracentesis shows clear, yellow-colored fluid with a protein concentration of 1.9 g/dL. Which of the following is the most likely underlying cause of this patient's pleural effusion?
A 65-year-old man is brought to the emergency department for a 1-week history of worsening shortness of breath. The symptoms occur when he climbs the stairs to his apartment on the 3rd floor and when he goes to bed. He gained 2.3 kg (5 lbs) in the past 5 days. He has a history of hypertension, hyperlipidemia, alcoholic steatosis, and osteoarthritis. He received surgical repair of a ventricular septal defect when he was 4 months old. He started taking ibuprofen for his osteoarthritis and simvastatin for his hyperlipidemia one week ago. He drinks 2–3 beers daily after work. His temperature is 37.0°C (98.6°F), his pulse is 114/min, and his blood pressure is 130/90 mmHg. Physical examination reveals jugular venous distention and 2+ pitting edema in his lower legs. On cardiac auscultation, an additional, late-diastolic heart sound is heard. Bilateral crackles are heard over the lung bases. Echocardiography shows concentric hypertrophy of the left ventricle. Which of the following is the most likely underlying cause of this patient's condition?
A 65-year-old man is brought to the emergency department after loss of consciousness. He is accompanied by his wife. He is started on intravenous fluids, and his vital signs are assessed. His blood pressure is 85/50 mm Hg, pulse 50/min, and respiratory rate 10/min. He has been admitted in the past for a heart condition. His wife is unable to recall the name of the condition, but she does know that the doctor recommended some medications at that time in case his condition worsened. She has brought with her the test reports from previous medical visits over the last few months. She says that she has noticed that he often has difficulty breathing and requires three pillows to sleep at night to avoid being short of breath. He can only walk for a few kilometers before he has to stop and rest. His wife also reports that he has had occasional severe coughing spells with pinkish sputum production. She also mentions that he has been drinking alcohol for the past 30 years. Which of the following medications will improve the prognosis of this patient?
Two days after emergency treatment for acute decompensated heart failure in the coronary care unit (CCU), a 68-year-old man develops palpitations. He has a history of ischemic heart disease and congestive heart failure for the last 10 years. His current medications include intravenous furosemide and oral medications as follows: carvedilol, aspirin, lisinopril, nitroglycerin, and morphine. He has received no intravenous fluids. The vital signs include: blood pressure 90/70 mm Hg, pulse 98/min, respiratory rate 18/min, and temperature 36.8°C (98.2°F). On physical examination, he appears anxious. The lungs are clear to auscultation. Cardiac examination reveals no change compared to the initial exam, and his peripheral edema has become less significant. There is no edema in the back or sacral area. Urine output is 1.5 L/12h. Serial electrocardiogram (ECG) reveals no dynamic changes. The laboratory test results are as follows: Laboratory test Serum Urea nitrogen 46 mg/dL Creatinine 1.9 mg/dL Na+ 135 mEq/L K+ 3.1 mEq/L Arterial blood gas analysis on room air: pH 7.50 PCO2 44 mm Hg PO2 88 mm Hg HCO3− 30 mEq/L Which of the following is the most likely explanation for this patient’s current condition?
A 67-year-old man with a past medical history of sleep apnea presents to the emergency room in severe respiratory distress. On exam, his blood pressure is 135/75 mmHg, heart rate is 110/min, respiratory rate is 34/min, and SpO2 is 73% on room air. He is intubated, admitted to the intensive care unit, and eventually requires a tracheostomy tube. After surgery, he continues to have episodes of apnea while sleeping. What is the most likely underlying cause of his apnea?
Explanation: ***Increased pulmonary capillary pressure*** - The patient's symptoms (epigastric pain, sweating, breathlessness) and risk factors (hypertension, smoking) suggest an **acute coronary syndrome**, which can lead to left ventricular dysfunction and **cardiogenic pulmonary edema**. - **Increased pulmonary capillary pressure** (due to elevated left atrial and pulmonary venous pressures) causes fluid transudation into the alveoli, leading to V/Q mismatch and hypoxemia (low pO2). *Increased pulmonary capillary permeability* - This typically occurs in conditions causing **acute respiratory distress syndrome (ARDS)**, such as sepsis or trauma, which are not suggested by the patient's presentation. - While ARDS can cause hypoxemia, the primary cause would be fluid leakage due to inflammation, not hydrostatic pressure increase. *Decreased total body hemoglobin* - This would lead to **anemic hypoxia**, where oxygen delivery is impaired due to insufficient oxygen-carrying capacity, but the pO2 (partial pressure of oxygen) in the arterial blood itself would not necessarily be low. - The problem here is in gas exchange, indicated by the low pO2, rather than the amount of hemoglobin. *Decreased transpulmonary pressure* - This refers to the pressure difference across the lung, important for lung inflation. Decreased transpulmonary pressure might occur in conditions like **pneumothorax** or **pleural effusion**, which are not indicated by the symptoms or blood gas results. - It would primarily affect lung volume and compliance, leading to hypoxemia indirectly through atelectasis or reduced ventilation. *Decreased minute ventilation* - **Hypoventilation** would cause both a low pO2 and an **elevated pCO2**, indicating insufficient CO2 removal. - This patient has a low pO2 but also a **low pCO2 (32 mm Hg)**, indicating **respiratory alkalosis from hyperventilation**, likely as a compensatory response to hypoxemia and the physiologic stress of acute myocardial infarction.
Explanation: ***Mitral annular dilatation*** - The combination of **shortness of breath**, **fatigue**, **S3 gallop**, and a **holosystolic murmur** at the apex in the peripartum period is highly suggestive of **peripartum cardiomyopathy (PPCM)**. - In PPCM, the **left ventricle dilates**, leading to **mitral annular dilatation** and subsequent **functional mitral regurgitation**, which manifests as a holosystolic murmur. The resolution of symptoms and murmur after treatment supports PPCM. *Myxomatous mitral valve degeneration* - This condition is characterized by **structural changes** in the mitral valve leaflets, making them redundant or prolapsing. - The murmur associated with this would likely be a **mid-systolic click** followed by a late systolic murmur, and it would typically be a **chronic finding** that would not resolve within weeks postpartum. *Mitral annular calcification* - This condition involves thickening and hardening of the **mitral valve annulus**, primarily seen in older individuals or those with significant cardiovascular risk factors. - While it can lead to mitral regurgitation or stenosis, it is a **chronic structural change** and would not resolve spontaneously or with medical management in a few weeks. *Perivalvular abscess* - A perivalvular abscess is a complication of **infective endocarditis**, typically presenting with **fever**, positive **blood cultures**, and evidence of infection. - This patient lacks fever or other signs of infection, and the rapid resolution of symptoms and murmur is inconsistent with an active infectious process requiring specific antibiotic therapy. *Mitral valve leaflet fibrosis* - **Mitral valve leaflet fibrosis** implies a **scarring and thickening of the valve leaflets**, often a consequence of rheumatic heart disease or other chronic inflammatory processes. - This is a **permanent structural change** that would not resolve spontaneously within weeks after delivery, and the patient has no history to suggest such a condition.
Explanation: ***Elevated brain natriuretic peptide*** - This patient presents with symptoms of **dyspnea**, **chest pain**, **tachycardia**, elevated **troponin I**, an enlarged **cardiac silhouette** with prominent vascular markings, and **blunted costophrenic angles**, all consistent with **cardiomyopathy** and heart failure, likely post-viral **myocarditis**. - **Brain natriuretic peptide (BNP)** is released by myocardial cells in response to ventricular stretch and volume overload, making it a strong indicator for **heart failure**. *Opening snap with low-pitched diastolic rumble* - An **opening snap** followed by a **low-pitched diastolic rumble** is characteristic of **mitral stenosis**, a valvular disorder not suggested by the patient's acute presentation and other findings. - Mitral stenosis would typically be associated with a history of **rheumatic fever** and more specific echocardiographic findings of valve abnormalities. *Sarcomere duplication* - **Sarcomere duplication** and disarray are characteristic pathological findings in **hypertrophic cardiomyopathy (HCM)**, an inherited genetic disorder. - While HCM can cause dyspnea and chest pain, this patient's acute presentation following a viral infection and evidence of fluid overload are more indicative of an **acquired cardiomyopathy** such as myocarditis. *Right ventricular dilation* - While the patient has signs of **heart failure**, the chest X-ray shows an **enlarged cardiac silhouette** and **prominent vascular markings in both lung fields** and **blunted costophrenic angles**, suggesting **left ventricular failure** with fluid redistribution and pleural effusions. - Significant **right ventricular dilation** would typically be associated with signs of right-sided heart failure like **peripheral edema** and **jugular venous distension**, which are not explicitly mentioned as primary findings. *Electrical alternans* - **Electrical alternans** is a specific ECG finding characterized by beat-to-beat variation in the QRS amplitude or axis, most commonly associated with **pericardial effusion** leading to cardiac tamponade. - Although the patient has an enlarged cardiac silhouette, which could indicate effusion, the primary findings point more broadly to **myocardial dysfunction** and **heart failure** rather than tamponade.
Explanation: ***Oxygen therapy*** - This patient has **severe COPD** (FEV1 27% predicted) and **chronic hypoxemia** (SpO2 84-88%). Long-term oxygen therapy (LTOT) is proven to increase survival in such patients by reducing **pulmonary hypertension** and improving cardiac function. - The goal of LTOT is to maintain a **PaO2 > 60 mmHg** or an **SaO2 > 90%** at rest, during sleep, and with exertion. *Inhaled fluticasone* - While inhaled corticosteroids like fluticasone can reduce exacerbations in patients with severe COPD and frequent exacerbations, they do not consistently improve **survival** in the way oxygen therapy does for chronic hypoxemia. - This patient is already on budesonide, another inhaled corticosteroid, making an additional ICS unlikely to provide significant further survival benefit. *Antibiotic therapy* - **Antibiotics** are used to treat acute bacterial exacerbations of COPD, which this patient recently experienced and has improved from (cough and chills have improved). - There is no indication for **chronic antibiotic therapy** for survival benefit in stable COPD unless there are specific indications like frequent exacerbations or bronchiectasis. *Oral roflumilast* - **Roflumilast** is a phosphodiesterase-4 inhibitor used in severe COPD with a history of exacerbations to reduce exacerbation frequency, particularly in patients with chronic bronchitis phenotype. - While it can improve lung function and reduce exacerbations, it has not been shown to improve **survival** directly. *Oral theophylline* - **Theophylline** is a bronchodilator with a narrow therapeutic window and potential for significant side effects, often used as an alternative or add-on therapy in COPD. - While it can improve symptoms and lung function, it has not been demonstrated to improve **survival** in patients with severe COPD and chronic hypoxemia.
Explanation: ***Regular phlebotomy*** - The patient's presentation with **heart failure** symptoms (fatigue, shortness of breath, leg swelling, JVD, S3, crackles, enlarged liver, reduced LVEF) combined with **arthralgias**, **diabetes**, and **hyperpigmented (tanned/dark brown) skin** is highly suggestive of **hereditary hemochromatosis**. - **Regular phlebotomy** is the primary treatment for **hemochromatosis** to reduce iron overload and prevent end-organ damage, including **dilated cardiomyopathy**, which is the cause of his heart failure. *Smoking cessation* - While **smoking** is a significant risk factor for **cardiovascular disease** and contributes to overall morbidity, it is not the primary underlying cause of the specific constellation of symptoms seen here (heart failure, arthralgias, diabetes, and hyperpigmented skin) that points toward **hemochromatosis**. - **Smoking cessation** would improve general health but would not have prevented the iron overload and subsequent organ damage characteristic of this patient's condition. *Nocturnal continuous positive airway pressure therapy* - **Snoring** suggests possible **sleep apnea**, and CPAP therapy would address this. - However, **sleep apnea** does not explain the widespread organ damage indicators like diabetes, arthralgias, and hyperpigmented skin, nor is it the primary cause of this specific type of cardiomyopathy. *Protective clothing* - The patient went camping in northern New York, which could increase the risk of **Lyme disease** or other **tick-borne illnesses**. - While protective clothing might prevent **tick bites**, the clinical picture of chronic heart failure, diabetes, arthralgias, and hyperpigmentation is not typical of **Lyme disease**, which usually presents with migratory arthralgias, rash, and specific neurological or cardiac manifestations not fully matching this case. *Surgical valve repair* - The echocardiogram shows **mild mitral regurgitation**, which is likely a consequence of the **left ventricular enlargement** and dilation due to the cardiomyopathy, rather than a primary valvular defect. - Addressing the underlying cause of the cardiomyopathy (**iron overload due to hemochromatosis**) would be more appropriate than surgically intervening on a mildly incompetent valve that is secondary to the primary disease process.
Explanation: ***Congestive heart failure*** - The **clear, yellow-colored fluid** with a **protein concentration of 1.9 g/dL** (indicating a protein level less than 3 g/dL) is characteristic of a **transudative pleural effusion**. - **Congestive heart failure** is the most common cause of transudative effusions, due to increased **hydrostatic pressure** in pleural capillaries. *Thoracic duct injury* - A **thoracic duct injury** would lead to a **chylous effusion**, which is typically milky in appearance due to high triglyceride content. - The fluid in this case is described as clear and yellow, not milky. *Pulmonary tuberculosis* - **Tuberculosis** typically causes an **exudative effusion** with higher protein levels (>3 g/dL) and often lymphocytes. - The fluid described here has a low protein level, characteristic of a transudate. *Bacterial pneumonia* - **Bacterial pneumonia** causes a **parapneumonic effusion**, which is typically exudative with high protein, high LDH, and often contains neutrophils. - The **low protein content** of the fluid (1.9 g/dL) rules out an exudative process like bacterial pneumonia. *Pulmonary sarcoidosis* - **Pulmonary sarcoidosis** can cause pleural effusions, but these are usually **exudative** with elevated protein and lymphocytes, sometimes resembling tuberculosis. - The **transudative nature** of the effusion described in the patient (low protein) is inconsistent with sarcoidosis.
Explanation: ***Arterial hypertension*** - The patient exhibits several signs of **heart failure** (shortness of breath, weight gain, jugular venous distention, edema, crackles) and **concentric left ventricular hypertrophy** on echocardiography, which is a classic adaptation to chronic pressure overload due to poorly controlled hypertension. - While the patient has a history of hypertension, his blood pressure of 130/90 mmHg might be an acute measurement; chronic, untreated, or poorly managed hypertension can lead to severe cardiac remodeling and failure. - **Note**: While recent **ibuprofen use** (an NSAID) likely **precipitated** this acute decompensation through sodium retention and renal effects, the question asks for the **underlying cause**, which is the chronic hypertension that resulted in the pathologic concentric LVH. *Alcoholic cardiomyopathy* - Although the patient consumes alcohol regularly (2-3 beers daily), **alcoholic cardiomyopathy** typically presents with **dilated cardiomyopathy**, characterized by ventricular dilation and systolic dysfunction, not concentric hypertrophy. - The clinical picture of concentric hypertrophy points towards chronic pressure overload rather than alcohol-induced direct myocardial toxicity leading to dilation. *Flow reversal of ventricular shunt* - A ventricular septal defect (VSD) repair at 4 months of age suggests a corrected congenital heart defect. **Flow reversal of a ventricular shunt** (e.g., Eisenmenger syndrome due to an uncorrected VSD) would typically present with **cyanosis** and pulmonary hypertension, which are not mentioned. - Given the successful repair in infancy, this is unlikely to be the primary cause of heart failure with left ventricular hypertrophy decades later. *Recent use of simvastatin* - **Simvastatin** is a statin used to lower cholesterol and is generally **cardioprotective**, posing a very low risk of causing acute heart failure or exacerbating it. - While statins can rarely cause myopathy, this does not explain the sudden onset of heart failure symptoms and concentric hypertrophy. *Pericardial effusion* - **Pericardial effusion** would typically cause symptoms related to **cardiac tamponade** (e.g., muffled heart sounds, pulsus paradoxus, electrical alternans) if significant. - It would not directly cause **concentric left ventricular hypertrophy**, which is a consequence of chronic pressure overload on the myocardium itself, not pericardial fluid accumulation.
Explanation: **Enalapril** - This patient presents with signs and symptoms of **decompensated heart failure** (dyspnea, orthopnea, pinkish sputum, hypotension, bradycardia). **ACE inhibitors** like enalapril are cornerstone treatments for heart failure, improving remodeling and prognosis. - ACE inhibitors reduce preload and afterload, decrease sympathetic activity, and prevent cardiac remodeling, all contributing to improved long-term outcomes and survival in **chronic heart failure**. *Furosemide* - **Furosemide** is a loop diuretic that provides symptomatic relief of congestion and fluid overload in heart failure by increasing fluid excretion. - While it improves symptoms and may be critical in acute decompensation, **furosemide does not directly improve the long-term prognosis** or survival in chronic heart failure. *Digoxin* - **Digoxin** is a positive inotrope that can improve symptoms and reduce hospitalizations in patients with systolic heart failure and atrial fibrillation. - However, **digoxin does not consistently improve overall mortality** or prognosis in heart failure patients with sinus rhythm, and its use is limited by a narrow therapeutic index. *Amiodarone* - **Amiodarone** is an antiarrhythmic medication primarily used for ventricular and supraventricular arrhythmias, particularly in patients with structural heart disease. - While it can manage arrhythmias that might complicate heart failure, **amiodarone does not improve the underlying prognosis** of heart failure itself. *Amlodipine* - **Amlodipine** is a calcium channel blocker primarily used to treat hypertension and angina. It can cause peripheral edema and may worsen symptoms in some heart failure patients. - Dihydropyridine calcium channel blockers like amlodipine are generally **neutral or may be detrimental in heart failure** with reduced ejection fraction and do not improve prognosis.
Explanation: ***Iatrogenic dehydration*** - The patient's **hypotension** (BP 90/70 mmHg), **tachycardia** (pulse 98/min), significant **reduction in peripheral edema**, and **clear lungs** suggest effective diuresis but potentially excessive fluid loss. - Signs of **acute kidney injury** (elevated BUN and creatinine, with a BUN/creatinine ratio of 24, indicating prerenal azotemia) and **hypokalemia** (K+ 3.1 mEq/L) further support a state of dehydration exacerbated by furosemide. *Hospital delirium* - While the patient appears anxious, there are no specific signs of **disorientation, altered consciousness, or cognitive fluctuation** that would strongly indicate delirium. - The patient's symptoms are more consistent with a physiological response to fluid and electrolyte imbalance rather than a primary neuropsychiatric condition. *Exacerbation of heart failure* - The patient's improved peripheral edema, clear lungs, and reduced respiratory rate indicate an **improvement in heart failure congestion**, not an exacerbation. - The hypotension and tachycardia are more indicative of volume depletion rather than worsening cardiac function due to fluid overload. *Oversedation* - The patient appears **anxious**, which is inconsistent with oversedation; oversedation would typically manifest as drowsiness, lethargy, or decreased mental status. - There is no clinical or medication-related evidence provided to suggest excess sedative use. *Excessive beta-adrenergic blockade* - While the patient is on carvedilol (a beta-blocker), his **tachycardia** (98/min) and **hypotension** are more consistent with hypovolemia rather than a primary effect of excessive beta-blockade. - Excessive beta-blockade would typically cause **bradycardia** and potentially worsen heart failure if severe, which is contrary to the clinical picture of decongestion.
Explanation: ***Central sleep apnea*** - Despite having a **tracheostomy**, the patient continues to experience **apnea while sleeping**, which indicates a problem with the **central respiratory drive** rather than an upper airway obstruction. - A tracheostomy bypasses the upper airway, eliminating **obstructive causes** of apnea; therefore, persistent apnea points to a **neurological issue** where the brain fails to send signals to the respiratory muscles. *Obstructive sleep apnea* - This is unlikely to be the primary cause of his persistent apnea because the **tracheostomy tube** effectively **bypasses any potential upper airway obstruction**. - While he had a prior history of sleep apnea, the continuation of apnea despite an open airway through the tracheostomy suggests a different underlying mechanism. *Incorrect ventilator settings* - The question states the patient "continues to have episodes of apnea while sleeping," implying these events occur independently of active ventilation, typically when the patient is attempting to **breathe spontaneously**. - Ventilator settings would be relevant during mechanical ventilation, but not for **spontaneous apneic episodes** during sleep after extubation or while on a tracheostomy, which points to a **respiratory drive issue**. *Heart failure* - While **heart failure** can be an **underlying etiology** of central sleep apnea (causing **Cheyne-Stokes respiration**), the question asks for the **mechanism/type** of apnea occurring. - The key clinical finding is persistent apnea **despite tracheostomy**, which identifies the **mechanism as central** (loss of respiratory drive), not obstructive. - **Central sleep apnea** is the direct answer describing the type of breathing disorder; heart failure would be a possible underlying cause of the CSA, but not the mechanism itself. *Angioedema* - **Angioedema** causes **upper airway obstruction** due to swelling. - This condition would be **relieved by the tracheostomy** and would not cause persistent apnea *after* its insertion.
Explanation: ***Early diastolic extra heart sound*** - The patient's symptoms (dyspnea, orthopnea, paroxysmal nocturnal dyspnea) and holosystolic murmur at the apex are consistent with **mitral regurgitation**, leading to **left ventricular dysfunction** and elevated left atrial pressures. - An early diastolic extra heart sound, or an **S3 gallop**, indicates increased left ventricular end-diastolic pressure and volume overload, a classic finding in **decompensated heart failure**. - This is a key sign of **acute exacerbation** when heart failure worsens. *Head bobbing* - **Head bobbing** (De Musset's sign) is a peripheral sign of **severe aortic regurgitation**, not mitral regurgitation. - This sign represents the rhythmic bobbing of the head with each heartbeat due to the large pulse pressure from AR. *Prominent V wave* - A prominent V wave in the jugular venous pressure waveform is associated with **tricuspid regurgitation**, reflecting increased right atrial pressure during ventricular systole. - While jugular venous distention can occur in severe biventricular failure, this specific finding is characteristic of TR, not MR exacerbation. *Radiation of the murmur to the axilla* - **Radiation of the murmur to the axilla** is a characteristic finding of the **mitral regurgitation murmur itself**, present at baseline in this patient. - This describes the location and transmission of the existing murmur, not a new finding indicating acute exacerbation or decompensation. - The question asks for a sign of exacerbation, requiring evidence of worsening heart failure. *Absence of A2 heart sound* - **Absence of the A2 heart sound** suggests severe **aortic stenosis**, where the aortic valve leaflets are so rigid and immobile they do not produce an audible closing sound. - This finding is unrelated to mitral regurgitation or its exacerbation.
Explanation: ***Abstinence from alcohol*** - This patient presents with signs and symptoms consistent with **dilated cardiomyopathy** and **heart failure**, including dyspnea, palpitations, S3 gallop, displaced PMI, JVD, crackles, and pitting edema. His 30-year history of heavy daily alcohol consumption strongly suggests **alcoholic cardiomyopathy** as the underlying cause. - **Abstinence from alcohol** is the most crucial and effective measure to prevent further progression of myocardial damage and often leads to significant improvement or even reversal of alcoholic cardiomyopathy. *Salt and fluid restriction* - While salt and fluid restriction are essential components of heart failure management to reduce fluid overload and its symptomatic effects, they address the **manifestations of heart failure** rather than the underlying cause of this patient's cardiomyopathy. - This step would be appropriate as adjunctive therapy, but not the most appropriate initial step for managing the **underlying etiology**. *Thiamine substitution* - **Thiamine deficiency** can lead to **wet beriberi**, which presents as high-output cardiac failure. However, this patient's presentation with an S3 gallop and displaced PMI is more indicative of dilated cardiomyopathy and low-output heart failure exacerbated by alcohol. - While chronic alcoholics are at risk for thiamine deficiency and it might be considered to rule out beriberi, it's not the primary underlying cause for the described dilated cardiomyopathy, and **alcohol abstinence** directly targets the most likely etiology. *Levothyroxine substitution* - **Hypothyroidism** can lead to symptoms like fatigue, bradycardia, and sometimes pericardial effusions or impaired myocardial contractility, but it rarely presents with the prominent dilated cardiomyopathy and overt heart failure signs described here. - This patient's symptoms are not typical for hypothyroidism, and there's nothing in the history to suggest thyroid dysfunction. *Dietary iron restriction* - **Hemochromatosis** is a genetic disorder leading to iron overload, which can cause **restrictive cardiomyopathy** or dilated cardiomyopathy. However, there is no mention of other typical symptoms of hemochromatosis like skin bronzing, diabetes, or liver dysfunction. - In the absence of evidence for iron overload, and given the strong history of chronic heavy alcohol use, dietary iron restriction is not the most appropriate intervention for this patient's symptoms.
Explanation: ***Rupture of the posteromedial papillary muscle of the left ventricle*** - The patient's presentation with acute decompensated heart failure following a STEMI, new holosystolic murmur radiating to the axilla, S3, and bilateral crackles is highly suggestive of acute **mitral regurgitation**. - The posteromedial papillary muscle is particularly susceptible to ischemic injury and rupture after an **inferior or posterior STEMI** because it has a **single blood supply** from the posterior descending artery (PDA), making it a common complication within days to weeks post-MI. *Rupture of the septal papillary muscle on the right ventricle* - The right ventricle does not have "septal" papillary muscles; it has anterior, posterior, and septal papillary muscles, but a distinct "septal papillary muscle on the right ventricle" causing systemic symptoms like those described is anatomically incorrect in this context. - Right ventricular papillary muscle rupture would primarily affect the **tricuspid valve**, leading to **tricuspid regurgitation**, which typically presents with signs of **right-sided heart failure** (e.g., jugular venous distention, hepatomegaly) rather than a murmur radiating to the axilla. *Rupture of the posterior papillary muscle on the right ventricle* - Rupture of a posterior papillary muscle of the right ventricle would primarily cause **tricuspid regurgitation**, not mitral regurgitation. - This would lead to signs of **right heart failure**, and the murmur would typically be heard loudest at the **lower left sternal border**, intensifying with inspiration, not radiating to the axilla. *Rupture of the anterolateral papillary muscle of the left ventricle* - While rupture of the anterolateral papillary muscle can cause acute mitral regurgitation, it is **less common** than posteromedial rupture. - This is because the anterolateral papillary muscle has a **dual blood supply** from both the left anterior descending (LAD) and circumflex arteries, making it more resistant to ischemia. *Rupture of the anterior papillary muscle of the right ventricle* - This would result in **tricuspid regurgitation**, not mitral regurgitation. - Symptoms would be consistent with **right heart failure**, and the murmur's characteristics would differ from those described (e.g., location, radiation).
Explanation: ***Extra heart sound in early diastole*** - The patient's symptoms (dyspnea, orthopnea, paroxysmal nocturnal dyspnea, jugular venous distention, edema) are classic for **congestive heart failure (CHF)**. - An **S3 gallop** is an extra heart sound occurring in **early diastole** and is pathognomonic for **volume overload** and **ventricular dysfunction** in CHF. *Opening snap* - An **opening snap** is typically heard in **mitral stenosis**, which is not directly indicated by the patient's symptoms of volume overload from heart failure. - This sound occurs shortly after S2 as the stenotic mitral valve opens. *Extra heart sound in late diastole* - An extra heart sound in **late diastole** is often an **S4 gallop**, which indicates **poor ventricular compliance** (e.g., in hypertension or aortic stenosis) rather than the pronounced volume overload suggested by the current presentation. - An S4 is heard just before S1, as the atria contract to push blood into a stiff ventricle. *Fixed splitting* - **Fixed splitting of S2** is characteristic of an **atrial septal defect (ASD)**, where there is a constant delay in pulmonic valve closure, independent of respiration. - This is not a typical finding in the context of acute decompensated heart failure as described. *Parasternal holosystolic murmur* - A **parasternal holosystolic murmur** is typically associated with **ventricular septal defect (VSD)** or **tricuspid regurgitation**. - While tricuspid regurgitation can occur secondary to right heart failure, the most immediate and common auscultatory finding for overall heart failure with volume overload is an S3.
Explanation: ***Left ventricular dysfunction with functional mitral regurgitation following myocardial infarction*** - This is the **primary mechanism** underlying this patient's illness. The patient had an **anterolateral STEMI 6 years ago**, which caused **left ventricular dysfunction (LVEF 40%)**. - The **laterally displaced apical impulse** indicates **LV dilatation**, and the **4/6 holosystolic murmur at the apex that increases with breath-holding** (increased afterload) is characteristic of **functional mitral regurgitation** due to LV dilatation and papillary muscle displacement. - **Chronic LV failure** leads to **pulmonary hypertension**, which subsequently causes **RV dilatation and functional tricuspid regurgitation** (explaining the right-sided heart failure symptoms: JVD, ascites, peripheral edema). - The question asks for the mechanism that applies to the patient's illness—the **root cause** is **ischemic cardiomyopathy with functional MR**, with right heart failure being a **secondary consequence**. *Right-ventricular dilatation with subsequent functional tricuspid valve dysfunction* - While the patient does have **RV dilatation and functional TR** (as evidenced by JVD, ascites, and peripheral edema), this represents a **downstream consequence** of chronic left heart failure, not the primary mechanism. - This option does not explain the **laterally displaced apex**, **reduced LVEF (40%)**, or the **holosystolic apical murmur** (which is MR, not TR; TR murmur is heard at the left lower sternal border). - The **primary pathology** is on the left side of the heart from the previous MI. *Thickening of the parietal pericardium with impaired filling of the heart* - This describes **constrictive pericarditis**, which presents with **equalization of diastolic pressures**, **Kussmaul's sign**, **pericardial knock**, and often a **normal ejection fraction**. - The patient has **reduced LVEF (40%)** and **valvular regurgitation**, indicating **myocardial dysfunction** rather than a restrictive filling pattern from pericardial disease. *Progressive myxomatous degeneration of the mitral valve leaflets* - This describes **mitral valve prolapse (MVP)** or **degenerative MR**, a primary valvular disorder typically seen in younger patients or those with connective tissue disorders. - The patient's **history of MI** and **LV dysfunction** make **functional (secondary) MR** much more likely than primary valvular degeneration. - Primary valvular disease would not explain the **reduced LVEF** or the **biventricular failure**. *Streptococcal infection followed by mitral valve dysfunction* - This describes **rheumatic heart disease**, which typically causes **mitral stenosis** (more common than pure MR) and occurs after childhood **group A streptococcal pharyngitis**. - The patient's age (67), absence of rheumatic fever history, **history of ischemic heart disease**, and **LV systolic dysfunction** make this diagnosis highly unlikely. - Rheumatic MR is usually chronic and stable, not progressively worsening over 4 months in the setting of recent cardiac history.
Explanation: ***Ejection fraction: 40% with increased left ventricular wall thickness*** - This patient presents with **chronic, poorly controlled hypertension** (20-year history, BP 150/120, hypertensive retinopathy with copper wiring and cotton wool spots) leading to **decompensated heart failure**. - Clinical signs of heart failure include **shortness of breath, fatigue, bibasilar rales, jugular venous distension, and bilateral pitting edema**. - The **irregularly irregular pulse suggests atrial fibrillation**, a common complication of hypertensive heart disease and left atrial enlargement. - The **laterally displaced apical pulse** indicates left ventricular enlargement, and combined with **reduced ejection fraction (40%)** confirms **heart failure with reduced ejection fraction (HFrEF)**. - In **advanced hypertensive heart disease**, the ventricle may show **mixed/eccentric hypertrophy** with both **increased wall thickness** (from chronic pressure overload) and **chamber dilatation** (from decompensation), resulting in reduced systolic function. - This represents **stage D hypertensive heart disease** with progression from concentric LVH to eccentric remodeling with systolic dysfunction. *Ejection fraction: 55% with dilated chambers and thin walls* - An EF of 55% is **borderline normal/preserved** and would be inconsistent with the **severely reduced systolic function** suggested by the clinical presentation of decompensated heart failure. - **Dilated chambers with thin walls** is the classic pattern of **non-ischemic dilated cardiomyopathy**, which typically presents with **EF <40%**, not 55%. - While this patient may have some chamber dilatation, the combination of long-standing hypertension with preserved/increased wall thickness makes this less likely than hypertensive heart disease. *Ejection fraction: 60% with normal left ventricular wall thickness* - An EF of 60% is **normal** and **normal LV wall thickness** would not explain the clinical picture. - This finding would be incompatible with the **severe decompensated heart failure** evident from bibasilar rales, JVD, and pitting edema. - The **laterally displaced apical pulse and irregularly irregular rhythm** indicate significant cardiac remodeling, not a structurally normal heart. *Ejection fraction: 65% with rapid early diastolic filling and slow late diastolic filling* - An EF of 65% indicates **preserved systolic function**, which contradicts the clinical evidence of **systolic heart failure** (laterally displaced apex, severe volume overload). - While **diastolic dysfunction** can occur in hypertensive heart disease, the described filling pattern doesn't clearly indicate the **impaired relaxation** pattern (reduced E/A ratio) typically seen in hypertensive heart disease. - The severity of this patient's presentation (bibasilar rales, JVD, peripheral edema) suggests **systolic dysfunction**, not isolated diastolic dysfunction. *Ejection fraction: 80% with regurgitant aortic valve* - An EF of 80% is **supranormal/hyperdynamic** and inconsistent with the clinical presentation of **decompensated heart failure**. - While **chronic aortic regurgitation** can cause LV dilatation and eventual heart failure, it typically presents with a **wide pulse pressure** and **bounding pulses**, and the history strongly points to **hypertensive etiology** rather than primary valvular disease. - Aortic regurgitation would not explain the **hypertensive retinopathy** or the **20-year history of hypertension** as the primary pathology.
Explanation: ***Eosinophilic granulomatosis with polyangiitis (EGPA)*** - This patient's presentation with late-onset **asthma**, prominent **eosinophilia**, evidence of **cardiac involvement** (dilated cardiomyopathy, elevated troponin, S3 gallop), and positive **anti-MPO (P-ANCA) antibodies** are all highly characteristic of EGPA (Churg-Strauss syndrome). - EGPA is a systemic vasculitis that typically affects individuals with a history of asthma and allergic rhinitis, leading to inflammation and damage in various organ systems, including the lungs, heart, and skin. *Extrinsic asthma* - While the patient has asthma and high IgE, **extrinsic asthma** alone does not explain the profound **eosinophilia (40%)**, **cardiac dysfunction (dilated cardiomyopathy, S3 gallop, elevated troponin)**, and positive **anti-MPO antibodies**. - Worsening asthma symptoms in this context suggest a systemic underlying condition rather than just a typical asthma exacerbation. *Chagas disease* - **Chagas disease** is caused by *Trypanosoma cruzi* and can lead to **dilated cardiomyopathy**, but it is primarily endemic to Central and South America, which is inconsistent with the patient's lifelong residence in the United States. - It would not explain the prominent **eosinophilia**, **asthma**, or **positive anti-MPO antibodies**. *Primary dilated cardiomyopathy* - **Primary dilated cardiomyopathy** can explain the cardiac findings (dilated left ventricle, reduced ejection fraction, S3 gallop), but it does not account for the patient's severe **eosinophilia**, **asthma**, and positive **anti-MPO antibodies**. - This diagnosis would be considered if other systemic causes were ruled out. *Loeffler's endocarditis* - **Loeffler's endocarditis** (also called eosinophilic endomyocardial disease) presents with marked **eosinophilia** and eosinophilic infiltration of the endocardium leading to restrictive cardiomyopathy. - However, this patient has **dilated** (not restrictive) cardiomyopathy, and Loeffler's does not explain the **positive anti-MPO antibodies** or the systemic vasculitis. In fact, Loeffler's endocarditis can occur as a **cardiac manifestation of EGPA**, making EGPA the more comprehensive and accurate diagnosis in this case.
Explanation: ***Intravenous diuretics*** - The patient presents with classic signs and symptoms of **acute decompensated heart failure**, such as progressive dyspnea, orthopnea, paroxysmal nocturnal dyspnea, bilateral crackles, S3 gallop, pitting edema, and elevated blood pressure with elevated heart rate due to fluid overload. - **Intravenous loop diuretics** (e.g., furosemide) are the most appropriate initial therapy to reduce preload, alleviate pulmonary and systemic congestion, and improve oxygenation. *Intravenous beta blockers* - While beta-blockers are a cornerstone of chronic heart failure management, **starting or acutely increasing beta-blocker dosage in acute decompensated heart failure** can worsen cardiac output and lead to symptomatic hypotension or cardiogenic shock. - Beta-blockers should generally be withheld or reduced during acute exacerbations and reinstituted once the patient is stable. *Echocardiography* - While an **echocardiogram** is essential for diagnosing the underlying cause and assessing cardiac function in heart failure, it is not the *best next step* in a patient presenting with acute, severe symptoms requiring immediate stabilization. - The patient's acute respiratory distress and hypoxemia necessitate immediate medical intervention to reduce fluid overload before detailed diagnostic imaging. *Cardiac stress testing* - **Cardiac stress testing** is used to evaluate for inducible ischemia in stable patients and is not appropriate in the setting of acute decompensated heart failure. - Performing a stress test on a patient with signs of fluid overload and respiratory distress would be dangerous and could exacerbate their condition. *Intravenous inotropes* - **Intravenous inotropes** (e.g., dobutamine, milrinone) are typically reserved for patients with evidence of **cardiogenic shock** or severe heart failure with persistent hypoperfusion despite optimal fluid management and diuretic therapy. - This patient, while acutely ill, primarily exhibits signs of fluid overload without clear evidence of severe hypoperfusion compromising end-organ function.
Explanation: ***Add hydralazine/isosorbide dinitrate*** - This patient is an **African-American** with **chronic HFrEF** who remains symptomatic despite ACE inhibitor and beta-blocker therapy. - The **A-HeFT trial** demonstrated that **hydralazine/isosorbide dinitrate** reduces mortality and hospitalization in **African-American patients** with **NYHA class III-IV heart failure**. - This combination is a **Class I recommendation** specifically for **self-identified African-American patients** with HFrEF who remain symptomatic on standard therapy (ACC/AHA guidelines). - Among the options provided, this is the most appropriate addition, though in current practice, consideration would also be given to adding an **aldosterone antagonist** (spironolactone/eplerenone) or **SGLT2 inhibitor** if not yet prescribed. *Increase the dose of lisinopril* - The patient is already on **lisinopril 40 mg daily**, which is the **maximal recommended dose** for heart failure. - Increasing the dose further would not provide additional benefit and could increase the risk of **hypotension**, **hyperkalemia**, or **renal dysfunction**. *Add amlodipine* - Amlodipine is a **dihydropyridine calcium channel blocker** that is generally **not recommended** for routine use in **HFrEF**. - While it is **safe** in HFrEF (unlike non-dihydropyridines), it does **not improve mortality or morbidity** and does not address the underlying heart failure pathophysiology. - It may be considered for refractory hypertension or angina in HFrEF patients, but this patient's BP is adequately controlled. *Add valsartan* - Valsartan is an **ARB** that would serve as an **alternative** to lisinopril (ACE inhibitor), not as an additional agent. - **Combining ACE inhibitor + ARB** is generally **avoided** due to increased risk of **hyperkalemia**, **hypotension**, and **renal impairment** without significant mortality benefit. - If an ARB were to be added, it would be in the form of **sacubitril/valsartan (ARNI)**, which would **replace** the ACE inhibitor, not supplement it. *Increase the dose of bisoprolol* - The patient is on **bisoprolol 20 mg**, but the typical **target dose for HFrEF is 10 mg daily**. - The patient is already at or above the recommended target dose, and further increases would risk **bradycardia**, **hypotension**, and **fatigue** without clear additional benefit. - Heart rate is already 81/min, suggesting adequate beta-blockade.
Explanation: ***Lisinopril*** - The patient presents with classic signs and symptoms of **heart failure**, including dyspnea on exertion, bilateral pitting edema, jugular venous distention, S3 gallop, cardiomegaly, and pulmonary edema. **ACE inhibitors** like lisinopril are cornerstone therapy for **heart failure with reduced ejection fraction (HFrEF)** and significantly reduce mortality. - They work by blocking the **renin-angiotensin-aldosterone system (RAAS)**, leading to **vasodilation**, reduced preload and afterload, and prevention of cardiac remodeling. *Propranolol* - While beta-blockers are used in heart failure, **non-selective beta-blockers** like propranolol are generally not preferred due to potential for exacerbating symptoms in acutely decompensated heart failure and lack of evidence for mortality benefit in this context. - **Cardioselective beta-blockers** (e.g., carvedilol, metoprolol succinate) are used in stable heart failure, but propranolol's broad effects make it less suitable for this specific indication, especially when there are signs of decompensation. *Digoxin* - Digoxin can improve symptoms and reduce hospitalizations in heart failure, but it **does not demonstrate a mortality benefit** in patients with heart failure. - It is primarily used for **symptom control** in patients with HFrEF, especially those with coexisting **atrial fibrillation**. *Furosemide* - Furosemide is a **loop diuretic** that is highly effective at reducing fluid overload and improving symptoms like pulmonary edema and peripheral edema in heart failure. - However, while it improves symptoms and quality of life, furosemide **does not independently reduce mortality** in heart failure. *Verapamil* - Verapamil, a **non-dihydropyridine calcium channel blocker**, is generally **contraindicated** in heart failure with reduced ejection fraction (HFrEF) because it can worsen cardiac function and increase mortality. - It has **negative inotropic effects**, which can further impair the already weakened pumping ability of the heart.
Explanation: ***Right ventricular failure*** - The patient's symptoms (dyspnea, dizziness on exertion) and signs (loud P2, increased **JVP**, palpable **RV impulse**) strongly suggest **pulmonary hypertension**. - Persistently elevated pulmonary arterial pressure leads to increased afterload on the **right ventricle**, causing **RV hypertrophy** followed by dilatation and eventual failure. *Tension pneumothorax* - This is an **acute life-threatening condition** characterized by sudden-onset dyspnea, pleuritic chest pain, and **tracheal deviation**, which are not described. - It would not cause a protracted 6-month history and the specific cardiac signs observed. *Abdominal aortic aneurysm* - An **AAA** is a localized **dilatation of the abdominal aorta**, typically asymptomatic until rupture. - It would not be associated with dyspnea, dizziness, or the specific cardiac examination findings of **pulmonary hypertension**. *Sarcoidosis* - Sarcoidosis is a multisystem **granulomatous disease** that can affect the lungs and heart, but it's not a direct consequence of the presenting signs of **pulmonary hypertension**. - While it *can* cause pulmonary hypertension, it's a primary disease, not a *risk* of developing from the described cardiovascular state. *Pulmonary abscess* - A **pulmonary abscess** is a localized infection in the lung, typically presenting with fever, cough with purulent sputum, and chest pain. - It is not a direct complication of **pulmonary hypertension** and does not fit the chronic presentation described.
Explanation: ***Increased production of brain natriuretic peptide*** - The patient's symptoms (orthopnea, dyspnea on exertion, S4 gallop, rales, edema, hepatojugular reflux) are classic for **congestive heart failure**. - In heart failure, the **ventricular cardiomyocytes** are stretched due to increased volume and pressure, leading to the compensatory release of **BNP** to promote vasodilation and diuresis. *Decreased expression of metalloproteinases* - **Matrix metalloproteinases (MMPs)** are often **upregulated** in heart failure, contributing to adverse cardiac remodeling, not decreased expression. - Their increased activity promotes degradation of the extracellular matrix, further impairing cardiac function. *Decreased collagen synthesis* - In heart failure, there is often an **initial compensatory increase in collagen synthesis** and deposition, leading to **fibrosis** and increased myocardial stiffness. - While chronic heart failure can lead to complex remodeling, a primary decrease in collagen synthesis is not the typical response. *Cardiomyocyte hyperplasia* - **Cardiomyocytes** are terminally differentiated cells with very limited proliferative capacity in adults; therefore, **hyperplasia** (increase in cell number) is not a significant mechanism of response to increased workload in heart failure. - Instead, the heart typically responds through **cardiomyocyte hypertrophy** (increase in cell size) and fibrosis. *Increased nitric oxide bioactivity* - In heart failure, **endothelial dysfunction** is common, leading to **reduced nitric oxide (NO) bioavailability** rather than increased bioactivity. - Reduced NO bioactivity contributes to increased vascular resistance and impaired vasodilation, exacerbating heart failure.
Explanation: ***Increased venous return*** - The combination of **orthopnea**, **S3 gallop**, and **hepatomegaly** indicates **heart failure**. The **continuous bruit** over the historical stab wound points to an **arteriovenous (AV) fistula**. - An AV fistula causes a substantial volume of blood to bypass the systemic circulation and return rapidly to the right heart, leading to **increased venous return** and subsequently **high-output heart failure**. *Decreased sympathetic output* - **Decreased sympathetic output** would typically lead to **vasodilation**, reduced heart rate, and decreased cardiac output, which contradicts the symptoms of **heart failure** observed here. - Heart failure often involves compensatory **increased sympathetic activity** to maintain cardiac function. *Increased pulmonary resistance* - While **increased pulmonary resistance** (as in pulmonary hypertension) can cause right-sided heart failure, it doesn't explain the presence of a **continuous bruit** or the **high-output nature** of the heart failure suggested by the AV fistula. - Pulmonary resistance would typically reduce venous return to the left side of the heart, not primarily increase early venous return to the right heart like an AV fistula. *Increased peripheral resistance* - **Increased peripheral resistance** would make it harder for the heart to pump blood forward (increased afterload) and would not directly cause the **high-output state** seen with an AV fistula. - The **warm skin** observed in this patient is actually more consistent with **vasodilation** and **low systemic vascular resistance**, common in high-output heart failure. *Decreased contractility* - **Decreased contractility** (systolic dysfunction) is a common cause of heart failure, but in the context of an **AV fistula**, the primary issue is the **excessive volume load** on the heart, leading to high-output failure, rather than intrinsic myocardial weakness. - The heart initially attempts to compensate for the increased preload, but eventually fails due to the sustained high volume.
Explanation: ***Coxsackievirus infection*** - The patient's recent **viral prodrome** ("cold" 2 weeks ago) followed by rapid onset of heart failure symptoms, including **dilated cardiomyopathy** (global hypokinesis, EF 39%), is highly suggestive of **viral myocarditis**, with Coxsackievirus being a common cause. - Findings like a **third heart sound (S3)**, **displaced point of maximal impact (PMI)**, **2+ pitting edema**, and ECG abnormalities (PVCs, widened QRS) are consistent with **heart failure** secondary to myocardial damage. *Amyloidosis* - **Amyloidosis** typically causes **restrictive cardiomyopathy** or stiff heart syndrome, not dilated cardiomyopathy with global hypokinesis, and often presents in older patients with systemic involvement. - While it can cause heart failure, the sudden onset after a viral illness in a young patient makes it less likely. *Cocaine abuse* - **Cocaine abuse** can lead to cardiomyopathy, but it usually presents acutely with vasospasm and myocardial infarction, or chronic cardiomyopathy. - The patient's history of only occasional marijuana use and social drinking does not support significant substance abuse as the primary cause here. *Unstable angina* - **Unstable angina** is characterized by chest pain due to myocardial ischemia, but it does not directly explain global hypokinesis, a low ejection fraction, or the systemic signs of heart failure (edema, S3). - The symptoms are more consistent with myocardial dysfunction rather than transient ischemia. *Acute myocardial infarction* - While an **acute myocardial infarction (MI)** can cause heart failure, the patient's symptoms are more diffuse (global hypokinesis rather than regional wall motion abnormalities expected in an MI) and developed over two weeks after a viral illness. - An MI would typically present with more acute and severe chest pain, and the ECG findings (PVCs, widened QRS) are not definitive for an acute infarct without ST elevation or significant Q waves.
Explanation: ***Right ventricular dysfunction secondary to pulmonary hypertension*** - This patient's long history of smoking, chronic cough, and wheezing suggest significant **chronic obstructive pulmonary disease (COPD)**, which leads to **hypoxemia** and **pulmonary hypertension**. - **Pulmonary hypertension** increases the workload on the **right ventricle**, eventually leading to **right heart failure** (cor pulmonale), characterized by peripheral edema (leg swelling) and ascites (abdominal swelling). *Excessive protease activity* - While excessive protease activity (e.g., elastase) is implicated in the pathogenesis of **emphysema** by destroying alveolar walls, it does not directly cause peripheral edema and ascites. - This process primarily leads to **airflow obstruction** and **gas exchange abnormalities**, which can indirectly contribute to pulmonary hypertension but is not the direct cause of the peripheral edema. *Damage to kidney tubules* - **Acute tubular necrosis** or chronic kidney disease can cause edema due to impaired fluid and electrolyte balance, but the patient's symptoms (dyspnea, wheezing, smoking history) point strongly to a primary pulmonary and cardiac etiology. - While diabetes can cause nephropathy, there is no information to suggest acute kidney injury or chronic kidney disease leading to such severe edema. *Hyperplasia of mucous glands* - **Hyperplasia of mucous glands** in the bronchi is characteristic of **chronic bronchitis**, contributing to the chronic cough and airway obstruction. - This pathology primarily affects airway clearance and airflow, rather than directly causing systemic edema or ascites. *Defective protein folding* - **Defective protein folding**, such as in **alpha-1 antitrypsin deficiency**, can lead to early-onset emphysema and liver disease. - While this could fit with a pulmonary presentation, it is less common than smoking-induced COPD and does not directly explain the edema and ascites caused by right heart failure.
Explanation: ***Cardiac pump dysfunction*** - The patient exhibits signs of **cardiogenic shock**, including **hypotension** (87/64 mmHg), **tachycardia** (94/min), **crackles** in the lungs (pulmonary edema), **distended neck veins**, and cool, mottled extremities, all indicative of the heart's inability to effectively pump blood. - The progressive malaise, weakness, and confusion suggest **poor end-organ perfusion** due to severely impaired cardiac output. *Barrier to cardiac flow* - This typically refers to conditions like **pulmonary embolism** or **aortic stenosis**, where there's an obstruction to blood flow. - While pulmonary embolism can cause cardiogenic shock, the diffuse crackles are more suggestive of direct pump failure rather than an acute obstructive event. *Failure of vasoregulation* - This mechanism is characteristic of **distributive shock**, such as **septic shock** or anaphylactic shock, where there is widespread vasodilation leading to hypotension. - **Warm extremities** and a bounding pulse are usually seen in early distributive shock, contrasting with the patient's cool, cyanotic extremities. *Restriction of cardiac filling* - This occurs in conditions like **cardiac tamponade** or **constrictive pericarditis**, where external compression or stiffness of the heart limits its ability to fill. - While neck vein distension can be present, the extensive pulmonary crackles point more to direct pump failure leading to back pressure in the pulmonary circulation, rather than primary filling restriction. *Loss of intravascular volume* - This mechanism describes **hypovolemic shock**, which results from significant fluid loss due to hemorrhage, severe dehydration, or burns. - Patients in hypovolemic shock typically present with **flat neck veins**, increased heart rate, and cool extremities, but generally lack the prominent pulmonary crackles caused by fluid overload from heart failure.
Explanation: ***Decrease positive inspiratory pressure*** - The patient is experiencing worsening **hypotension** and **tachycardia** despite initial treatment, suggesting that the current BiPAP settings, particularly a high **positive inspiratory pressure (PIP)**, might be exacerbating the hemodynamic instability. - High intrathoracic pressure from BiPAP can decrease **venous return** and **cardiac preload**, further compromising an already struggling heart with reduced ejection fraction, leading to decreased cardiac output and worsening hypotension. *Decrease furosemide rate* - The patient has significant signs of **fluid overload** (pulmonary edema, JVD, pitting edema), and minimal urine output suggests inadequate diuresis, not over-diuresis. - Decreasing the furosemide rate would likely worsen fluid overload and pulmonary congestion, which is detrimental given his acute heart failure exacerbation. *Resume home metoprolol* - The patient is already hypotensive (90/50 mmHg initially, dropping to 75/40 mmHg) and in **cardiogenic shock**, and beta-blockers like metoprolol are **contraindicated** in this acute setting. - Resuming metoprolol would further depress myocardial contractility and worsen bradycardia (although he is currently tachycardic), significantly exacerbating his hypotension and shock state. *Decrease dobutamine rate* - **Dobutamine** is an **inotropic agent** used to improve cardiac contractility and cardiac output in patients with cardiogenic shock, especially with a low EF. - Decreasing the dobutamine rate would reduce inotropic support, likely leading to a further decline in cardiac output and worsening his profound hypotension and shock. *Decrease positive end-expiratory pressure* - While PEEP can increase intrathoracic pressure, the given BiPAP setting of 20/5 cm H2O indicates a PIP of 20 cm H2O and a **PEEP of 5 cm H2O**. A PEEP of 5 cm H2O is relatively low and often beneficial for oxygenation and reducing preload in pulmonary edema. - The primary concern for hemodynamic compromise with BiPAP is more often related to high peak inspiratory pressure reducing venous return, rather than a low PEEP which can help keep alveoli open and improve gas exchange.
Explanation: ***Congestive heart failure*** - **Chronic aortic regurgitation** leads to **volume overload** and **eccentric hypertrophy** of the left ventricle, eventually causing left ventricular dysfunction and **congestive heart failure**. - Symptoms like **fatigue** and **shortness of breath on exertion** are classic manifestations of heart failure, and cardiomegaly on CXR further supports this. *Arrhythmias* - While arrhythmias can occur with chronic aortic regurgitation due to chamber enlargement, they are generally **not the most common long-term complication** and often arise as a consequence of progressive heart failure. - The primary hemodynamic burden leads to heart failure first. *Infective endocarditis* - Patients with valvular heart disease, including aortic regurgitation, have an **increased risk of infective endocarditis**, but it is an acute complication rather than the most common long-term functional consequence of the valvular lesion itself. - The chronicity and severity of the regurgitation primarily lead to hemodynamic strain. *Sudden death* - Sudden death can occur in severe aortic regurgitation, especially in the context of advanced ventricular dysfunction or arrhythmias, but it is **less common than symptomatic congestive heart failure** as the leading long-term complication. - It often represents an end-stage event rather than the typical progression. *Myocardial ischemia* - Increased myocardial oxygen demand due to ventricular hypertrophy and reduced diastolic coronary filling time can lead to **myocardial ischemia in severe aortic regurgitation**, even in the absence of coronary artery disease. - However, the most widespread and debilitating long-term consequence of the volume overload and chamber dilation is the development of **heart failure**.
Explanation: ***Chronic hypoxia*** - The patient's history of **heavy smoking**, snoring with choking episodes suggestive of **sleep apnea**, and symptoms of **right-sided heart failure** (bilateral ankle swelling, JVD, right axis deviation on ECG) point to chronic hypoxia as the underlying cause. - **Chronic hypoxia** leads to **pulmonary vasoconstriction** and subsequent pulmonary hypertension, which eventually causes **right ventricular hypertrophy** and failure (cor pulmonale). *Alveolar destruction* - While **alveolar destruction** (emphysema) can lead to hypoxia in smokers, the normal auscultation of the lungs makes this less likely to be the primary cause of his symptoms, although it could contribute. - The **ECG showing right axis deviation** more strongly suggests a primary pulmonary vascular issue or sustained right ventricular strain rather than solely alveolar destruction. *Ischemic heart disease* - Although the patient has risk factors for **ischemic heart disease** (smoking, hypertension), his symptoms and signs (bilateral ankle swelling, JVD, right axis deviation, clear lungs) are more consistent with isolated **right-sided heart failure** due to a pulmonary issue, not acute or chronic ischemia. - **Left-sided heart failure** due to ischemic heart disease would typically present with pulmonary congestion (crackles, dyspnea) before isolated right-sided symptoms appear. *Left ventricular hypertrophy* - **Left ventricular hypertrophy** (LVH) is often seen in hypertension, but the patient's presentation of **right-sided heart failure** symptoms (JVD, edema, right axis deviation) with clear lungs does not directly point to LVH as the primary cause of his current condition. - While his hypertension could lead to LVH, the symptoms described are more consistent with **pulmonary hypertension** and cor pulmonale. *Chronic kidney damage* - **Chronic kidney damage** would explain the bilateral ankle swelling, but it would typically be associated with other signs like elevated creatinine, uremia, or proteinuria, which are not mentioned. - It would also not explain the **shortness of breath on exertion**, **snoring with choking**, or the **right axis deviation** on ECG, which directly points to a cardiac or pulmonary issue.
Explanation: ***Left ventricular eccentric hypertrophy*** - The symptoms of **dyspnea on exertion** and **paroxysmal nocturnal dyspnea** (relieved by propping up pillows) are classic for **left-sided heart failure**. - An **early diastolic gallop** (S3 heart sound) heard best at the apex in the left lateral decubitus position is indicative of **volume overload** and a failing, dilated left ventricle, consistent with eccentric hypertrophy. *Left ventricular concentric hypertrophy* - Concentric hypertrophy is typically associated with **pressure overload** (e.g., hypertension, aortic stenosis) and often presents with a **late diastolic gallop (S4)** due to a stiff, non-compliant ventricle. - While it can lead to heart failure, the presence of an **S3 gallop** points more strongly to a dilated, volume-overloaded ventricle. *Right atrial hypertrophy* - Right atrial hypertrophy results from **right ventricular dysfunction** or conditions like **pulmonary hypertension** and would manifest with symptoms of right heart failure (e.g., peripheral edema, jugular venous distention), not primarily left-sided symptoms. - It is not directly associated with a left ventricular early diastolic gallop. *Mitral stenosis* - Mitral stenosis typically causes a **mid-diastolic murmur** with an opening snap, and its symptoms are usually related to elevated left atrial pressure leading to pulmonary congestion and dyspnea. - An **S3 gallop** is not characteristic of mitral stenosis; it's more specific for left ventricular systolic dysfunction. *Left atrial hypertrophy* - Left atrial hypertrophy (enlargement) commonly results from conditions like **mitral valve disease** or **left ventricular diastolic dysfunction** but does not directly cause an S3 gallop. - While it contributes to symptoms of left heart failure, it's a consequence rather than the primary cause of an S3.
Explanation: ***Impaired relaxation of the right ventricle*** - The presence of **fatigue**, **abdominal discomfort**, **leg swelling**, **ascites with shifting dullness**, **hepatomegaly**, and particularly a positive **hepatojugular reflux** (jugular vein distension with RUQ pressure) strongly suggests **right-sided heart failure** due to impaired right ventricular relaxation, such as in **constrictive pericarditis** or **restrictive cardiomyopathy**. - **Ibuprofen (NSAID) use** and **joint tenderness** in the metacarpophalangeal joints hint at a potential underlying inflammatory condition like rheumatoid arthritis, which can be associated with **amyloidosis** causing restrictive cardiomyopathy. *Reduced glomerular filtration rate* - While a reduced GFR can cause edema, it typically leads to **generalized anasarca** and is often associated with symptoms of **uremia** or significant proteinuria, which are not described. - The prominent **hepatomegaly** and **positive hepatojugular reflux** are not primary features of renal-induced edema. *Macrovesicular steatosis of the liver* - **Macrovesicular steatosis** (fatty liver) itself does not directly cause significant edema or ascites unless it progresses to **cirrhosis**, which would manifest with more distinct signs of **liver failure** and portal hypertension. - While the patient has some alcohol intake, the clinical picture with prominent hepatojugular reflux points more towards cardiac than isolated liver pathology at this stage. *Dermal deposition of glycosaminoglycans* - Dermal deposition of **glycosaminoglycans** is characteristic of **myxedema** (hypothyroidism), which causes non-pitting edema and is usually associated with other symptoms like **cold intolerance**, **bradycardia**, and **dry skin**, none of which are mentioned. - The pitting edema observed in this patient is inconsistent with myxedema. *Impaired hepatic protein synthesis* - Impaired hepatic protein synthesis, leading to **hypoalbuminemia**, can cause edema and ascites due to reduced **oncotic pressure**. - However, the significant **hepatomegaly** and the distinct **hepatojugular reflux** are more indicative of a circulatory issue affecting the liver, rather than primary intrinsic liver failure.
Explanation: ***Decreased left myocardial compliance*** - A dull, low-pitched early **diastolic sound (S3 gallop)**, heard best in the left lateral decubitus position at end-expiration, indicates **rapid ventricular filling** into a ventricle with altered diastolic properties. This finding, along with worsening shortness of breath, lower extremity swelling, and weight gain, suggests **heart failure with impaired ventricular filling**. - Decreased left myocardial compliance (increased stiffness) means the left ventricle cannot **relax and fill properly** during diastole. The S3 occurs when blood rapidly decelerates as it enters the stiff, non-compliant ventricle, creating the characteristic sound. - This represents **diastolic dysfunction** (heart failure with preserved ejection fraction - HFpEF), which is common in elderly patients with hypertension and is characterized by a stiff ventricle with increased filling pressures. *Increased ventricular contractility* - Increased ventricular contractility would lead to a more forceful ejection of blood during systole, not an early diastolic filling sound. - This would not explain the S3 gallop or the signs of heart failure with fluid retention. *Increased capacity of the pulmonary circulation* - Increased pulmonary circulation capacity would help accommodate fluid and prevent pulmonary congestion, which contradicts the symptoms of crackles and shortness of breath. - The patient has **decreased** capacity to handle the fluid volume, leading to pulmonary edema. *Decreased left-ventricular filling pressure* - Decreased LV filling pressure would imply less fluid overload and better cardiac function, contrary to the clinical presentation. - An S3 gallop and signs of heart failure (crackles, edema, weight gain) indicate **increased** filling pressures from impaired ventricular function. *Increased left ventricular end-systolic volume* - Increased end-systolic volume indicates **systolic dysfunction** (reduced ejection fraction), where the ventricle cannot adequately eject blood, leaving residual volume after contraction. - While systolic dysfunction can also produce an S3 gallop due to volume overload, the specific clinical description emphasizes a **diastolic filling abnormality** (sound during early diastole in a specific position that optimizes detection of ventricular filling). - The S3 in systolic dysfunction is primarily due to **volume overload**, whereas the S3 here is attributed to blood entering a **stiff ventricle** with impaired compliance, which is the primary pathophysiologic mechanism being tested.
Explanation: **Chronic hypoxia** - The patient's history of **snoring, choking in sleep**, and progressive **dyspnea on exertion** suggests **sleep apnea**, leading to intermittent or chronic hypoxia. - **Chronic hypoxia** causes **pulmonary vasoconstriction**, leading to **pulmonary hypertension** and eventual **right heart failure**, evident by **jugular venous distention**, **lower extremity edema**, and **right axis deviation** on ECG. *Hypertensive nephropathy* - While the patient has **hypertension**, there's no direct evidence of **renal dysfunction** or signs like proteinuria or elevated creatinine that would indicate **hypertensive nephropathy** as the primary cause of his cardiac symptoms. - Although kidney dysfunction can lead to fluid retention, the entire clinical picture points more strongly to a pulmonary-cardiac etiology rather than primary renal failure. *Left ventricular hypertrophy* - **Left ventricular hypertrophy** is typically associated with **left heart failure**, which would present with symptoms like **pulmonary edema** (crackles on lung auscultation), not clear lungs. - The **right axis deviation** on ECG is indicative of **right heart strain** or **hypertrophy**, not left ventricular hypertrophy. *Coronary artery disease* - **Coronary artery disease (CAD)** often presents with **angina** or exertional chest pain, and while it can cause **heart failure**, the specific constellation of symptoms, especially the sleep-related issues and clear lungs, points away from primary CAD. - The **right axis deviation** is not a typical ECG finding for generalized CAD directly causing exertional dyspnea in this manner. *Alveolar destruction* - **Alveolar destruction**, as seen in severe **emphysema**, would cause **hypoxia** and could lead to **pulmonary hypertension** and **right heart failure**. - However, the patient's **lungs are clear to auscultation**, which makes significant **alveolar destruction** (e.g., from severe COPD) less likely compared to the strong evidence for **sleep apnea-induced hypoxia**.
Explanation: ***Congestive heart failure*** - The patient's presentation with **enlarged mandible**, **large hands**, and **numbness/tingling** suggests **acromegaly** due to excessive growth hormone. - **Cardiovascular complications**, such as **cardiomyopathy** leading to **congestive heart failure**, are the leading cause of mortality in patients with uncontrolled acromegaly. *Adrenal failure* - While endocrine disorders are present, **adrenal failure** is not a characteristic secondary complication or direct cause of mortality in acromegaly. - Acromegaly affects the pituitary gland, but typically leads to an **increase** in other hormones, not primary adrenal insufficiency. *Malignancy* - Patients with acromegaly have an **increased risk of certain malignancies**, particularly gastrointestinal and thyroid cancers. - However, **cardiovascular disease** remains the most common cause of mortality, preceding malignancy. *Kidney failure* - **Kidney failure** is not typically a direct or common cause of mortality associated with untreated acromegaly itself. - While uncontrolled diabetes (as suggested by the **fasting blood glucose of 155 mg/dL**) can lead to kidney damage, acromegaly's primary fatal complications are cardiovascular. *Stroke* - Patients with acromegaly have an increased risk of **hypertension and diabetes**, which are risk factors for stroke. - However, **cardiomyopathy and congestive heart failure** are more prevalent and a direct consequence of long-term growth hormone excess, making them the leading cause of death.
Explanation: ***Increased pulmonary capillary wedge pressure*** - The patient's symptoms of **fatigue**, **weakness**, **hypotension**, **tachycardia**, and **pulmonary congestion** (enlarged cardiac silhouette, bilateral pleural effusions) after a significant myocardial infarction are highly suggestive of **cardiogenic shock**. - In cardiogenic shock, the heart's pumping ability is severely compromised, leading to **increased end-diastolic filling pressures** in the left ventricle, which is reflected as an elevated **pulmonary capillary wedge pressure (PCWP)**. *Decreased systemic vascular resistance* - **Decreased systemic vascular resistance (SVR)** is a hallmark of **distributive shock**, such as septic shock, where widespread vasodilation occurs. - In **cardiogenic shock**, the body typically tries to compensate for reduced cardiac output by **increasing SVR** to maintain blood pressure, although this compensation may be overwhelmed, leading to hypotension. *Increased venous oxygen content* - **Increased mixed venous oxygen saturation (SvO2)** or **venous oxygen content** is seen when tissues are not adequately extracting oxygen, either due to shunt physiology or when oxygen delivery far exceeds demand. - In **cardiogenic shock**, tissue oxygen demand often exceeds delivery due to severely impaired cardiac output, leading to **increased oxygen extraction** by tissues and thus **decreased venous oxygen content**. *Increased ejection fraction* - The patient experienced a **large myocardial infarction (ST elevation in V2-V5)**, indicating substantial damage to the left ventricle. - This damage would severely impair the heart's pumping function, leading to a **decreased ejection fraction**, which is characteristic of **cardiogenic shock**. *Decreased tissue oxygen extraction* - **Decreased tissue oxygen extraction** would imply that tissues are not properly utilizing the delivered oxygen, or that oxygen delivery is so high that tissues don't need to extract as much. - In **cardiogenic shock**, cardiac output is severely reduced, leading to **inadequate oxygen delivery** to tissues, forcing them to **maximally extract oxygen** from the blood to meet metabolic demands.
Explanation: ***Inhibits release of renin*** - The patient's symptoms (shortness of breath, orthopnea, crackles, edema) and history of MI are consistent with **heart failure**, leading to increased natriuretic peptide production from cardiac myocytes due to ventricular stretch. - **Brain Natriuretic Peptide (BNP)**, released in heart failure, counteracts fluid retention by inhibiting renin release, thereby reducing aldosterone and angiotensin II, and promoting diuresis and natriuresis. *Increases water reabsorption in the kidney* - This is the primary function of **Antidiuretic Hormone (ADH)**, which acts on the collecting ducts to increase water reabsorption. - Natriuretic peptides, in contrast, promote water excretion rather than retention. *Stimulates parasympathetic nerves* - The **parasympathetic nervous system** primarily slows heart rate and promotes digestion through the vagus nerve. - Natriuretic peptides primarily exert their effects on the cardiovascular and renal systems to regulate blood volume and pressure, not through direct nervous system stimulation. *Increases conversion of angiotensin* - The conversion of angiotensin I to **angiotensin II** is mediated by **angiotensin-converting enzyme (ACE)**, primarily in the lungs. - The product described (natriuretic peptide) works to *inhibit* the renin-angiotensin-aldosterone system (RAAS), thus indirectly reducing angiotensin II levels. *Binds to intracellular receptors in the collecting duct* - Hormones that bind to **intracellular receptors** are typically steroid hormones (e.g., aldosterone, cortisol) that regulate gene expression. - Natriuretic peptides bind to **cell-surface receptors** (guanylyl cyclase receptors) on target cells, activating second messenger systems like cGMP.
Explanation: ***Enalapril*** - Enalapril, an **ACE inhibitor**, would prevent ventricular remodeling and worsening heart failure by blocking the **renin-angiotensin-aldosterone system (RAAS)**. - RAAS activation after an MI leads to **ventricular hypertrophy** and dilation, which ACE inhibitors effectively counteract. *Nifedipine* - **Nifedipine is a dihydropyridine calcium channel blocker** primarily used for hypertension and angina. - It does not have the same proven benefits in preventing ventricular remodeling or improving outcomes in **heart failure** as ACE inhibitors. *Atorvastatin* - **Atorvastatin is a HMG-CoA reductase inhibitor** that lowers cholesterol and stabilizes plaques. - While essential for **secondary prevention of cardiovascular events**, it does not directly prevent ventricular remodeling or improve ejection fraction in the setting of heart failure. *Diltiazem* - **Diltiazem is a non-dihydropyridine calcium channel blocker** that reduces heart rate and contractility. - It is generally **contraindicated** in patients with **reduced ejection fraction heart failure** as it can worsen cardiac function. *Digoxin* - **Digoxin is a positive inotrope** that can improve symptoms in heart failure but does not prevent ventricular remodeling or improve survival. - It has a **narrow therapeutic window** and is primarily used for symptom control in advanced heart failure or for rate control in atrial fibrillation.
Explanation: ***Thiamine*** - **Thiamine deficiency**, particularly in alcoholics, can lead to **wet beriberi**, characterized by **high-output cardiac failure** due to peripheral vasodilation, resulting in symptoms like tachycardia, bounding pulse, and warm extremities. - Thiamine (vitamin B1) is a crucial cofactor in carbohydrate metabolism, and its deficiency impairs myocardial energy production and causes systemic vasodilation. *Riboflavin* - **Riboflavin deficiency** (ariboflavinosis) typically presents with **cheilosis**, glossitis, angular stomatitis, and seborrheic dermatitis, and is not directly associated with high-output cardiac failure. - While it can occur in alcoholics, cardiac failure is not a prominent feature. *Vitamin B12* - **Vitamin B12 deficiency** primarily causes **megaloblastic anemia** and neurological symptoms such as **peripheral neuropathy**, ataxia, and cognitive impairment, rather than high-output cardiac failure. - Cardiac manifestations are usually due to severe anemia leading to compensatory high output, but not the primary cause as seen in thiamine deficiency. *Vitamin D* - **Vitamin D deficiency** is associated with **osteomalacia** in adults and rickets in children, leading to bone pain, muscle weakness, and increased fracture risk. - It does not cause high-output cardiac failure or related cardiovascular symptoms. *Niacin* - **Niacin deficiency** (pellagra) is characterized by the "3 Ds": **dermatitis**, **diarrhea**, and **dementia**, along with glossitis and stomatitis. - While cardiovascular symptoms can occur in severe cases, high-output cardiac failure with a bounding pulse is not a typical hallmark of pellagra.
Explanation: ***Carvedilol*** - The patient exhibits classic symptoms of **heart failure**, such as **dyspnea on exertion**, **orthopnea** (shortness of breath when he sleeps), and **lower extremity edema**. - **Beta-blockers** like carvedilol are essential for managing **chronic heart failure** by reducing myocardial oxygen demand and improving cardiac function. *Lidocaine* - **Lidocaine** is primarily an **antiarrhythmic drug** used for acute treatment of **ventricular arrhythmias**, not for chronic heart failure management. - It works by blocking sodium channels and has no direct benefit in addressing the underlying pathophysiology of heart failure. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** typically used for hypertension, angina, and supraventricular tachyarrhythmias. - It can have **negative inotropic effects**, which are generally contraindicated or used with extreme caution in patients with **systolic heart failure** due to its potential to worsen cardiac function. *Aspirin* - **Aspirin** is an **antiplatelet agent** used for primary or secondary prevention of **atherosclerotic cardiovascular disease** (e.g., in patients with coronary artery disease). - It does not directly manage the symptoms or pathophysiology of **heart failure** unless there is a coexisting ischemic etiology. *Ibutilide* - **Ibutilide** is an **antiarrhythmic drug** specifically used for the rapid conversion of **atrial flutter and atrial fibrillation** of recent onset to sinus rhythm. - It is not a medication used for the long-term management of **heart failure** symptoms described in the patient.
Explanation: ***Metoprolol*** - The patient's symptoms (shortness of breath on exertion, coughing while sleeping, crackles, edema) and medical history (hypertension, hyperlipidemia, diabetes) point to **chronic heart failure with reduced ejection fraction (HFrEF)**. The patient is already on lisinopril (an ACE inhibitor), which is one cornerstone of HF therapy. Beta-blockers like metoprolol are another crucial medication class proven to improve **long-term survival in HFrEF** by reducing cardiac remodeling, myocardial oxygen demand, and arrhythmias. - Metoprolol is a **selective beta-1 adrenergic blocker** that slows heart rate, reduces blood pressure, and decreases myocardial contractility, leading to improved cardiac efficiency and reduced mortality in chronic heart failure. The three beta-blockers with proven mortality benefit are metoprolol succinate, carvedilol, and bisoprolol. *Dobutamine* - **Dobutamine** is an inotropic agent used for **acute decompensated heart failure** to improve cardiac output and relieve symptoms in hospitalized patients. - It does not improve long-term survival and is typically used in the short term for patients with severe systolic dysfunction and hypoperfusion or cardiogenic shock. *Amlodipine* - **Amlodipine** is a dihydropyridine calcium channel blocker primarily used for **hypertension and angina**. - While it can lower blood pressure, it has **not been shown to improve long-term survival** in heart failure; some non-dihydropyridine calcium channel blockers (diltiazem, verapamil) may even worsen HF outcomes due to negative inotropic effects. *Digoxin* - **Digoxin** is a cardiac glycoside that improves symptoms and reduces hospitalizations in heart failure, particularly in patients with **atrial fibrillation** or persistent symptoms despite optimal therapy. - However, it has **not been shown to improve long-term survival** in heart failure (DIG trial showed neutral mortality effect) and has a narrow therapeutic window requiring monitoring. *Gemfibrozil* - **Gemfibrozil** is a fibrate used to treat **hypertriglyceridemia**. - It primarily affects lipid metabolism and has **no direct role in the management of heart failure** or in improving long-term survival in this context.
Explanation: ***Basilar crackles on pulmonary auscultation*** - **Left-sided heart failure** leads to increased pressure in the pulmonary veins, causing fluid to leak into the **pulmonary interstitium and alveoli**, manifesting as **basilar crackles** on auscultation. - This symptom is a direct result of **pulmonary congestion** and edema, which is not characteristic of isolated right-sided heart failure. *Abdominal fullness* - **Abdominal fullness** is typically a symptom of **right-sided heart failure**, due to **venous congestion** in the splanchnic circulation, leading to hepatomegaly and ascites. - While it can occur in severe biventricular failure, it is not a primary or earlier sign of isolated left-sided heart failure. *Hepatojugular reflex* - The **hepatojugular reflex** is a sign of **right ventricular dysfunction** and **elevated right atrial pressure**, indicating systemic venous congestion. - It is elicited by applying pressure to the liver, which causes a temporary increase in jugular venous distention. *Increased ejection fraction on echocardiogram* - **Heart failure**, whether left- or right-sided, is characterized by a **reduced (or preserved but not increased)** ejection fraction, reflecting impaired pumping ability. - An **increased ejection fraction** would indicate supra-normal cardiac function and is not associated with heart failure. *Lower extremity edema* - **Lower extremity edema** is a hallmark symptom of **right-sided heart failure**, as venous congestion leads to fluid accumulation in the peripheral tissues. - While present in biventricular failure, it is not a primary or early symptom of isolated left-sided heart failure.
Explanation: **Increased erythropoietin** - The patient's presentation of worsening **shortness of breath**, **wheezing**, and **cyanosis**, along with a **markedly decreased FEV1/FVC ratio**, indicates a severe **obstructive lung disease**, likely **COPD**. - **Chronic hypoxemia** (due to impaired gas exchange in severe obstructive lung disease) stimulates the kidneys to produce more **erythropoietin**, leading to secondary **polycythemia** to increase oxygen-carrying capacity. *Decreased serum bicarbonate* - **Decreased serum bicarbonate** typically indicates **metabolic acidosis**, which is not a primary or direct consequence of chronic obstructive lung disease. - In chronic respiratory conditions, the body often compensates for **respiratory acidosis** by **increasing bicarbonate retention**, leading to a normal or increased bicarbonate level. *Increased IgE* - **Elevated IgE** levels are characteristic of **atopic conditions** like **asthma** or allergic reactions, which are not explicitly suggested as the primary issue in this patient's chronic and progressive symptoms. - While asthma can have an obstructive pattern, the description of chronic worsening symptoms and cyanosis points more towards **COPD**, where IgE is not typically a direct distinguishing factor. *Pleural effusion* - **Pleural effusion** is an accumulation of fluid in the pleural space and would typically present with **dullness to percussion** and **decreased breath sounds** over the affected area, not primarily wheezing. - While some lung conditions can be complicated by pleural effusion, it is not a direct or most likely additional finding based on the presented symptoms of obstructive lung disease. *Nasal polyps* - **Nasal polyps** are benign growths in the nasal passages and are often associated with conditions like **aspirin-exacerbated respiratory disease** or **chronic rhinosinusitis**. - They are not a direct or common additional finding in the context of the severe and chronic obstructive lung disease described with systemic hypoxemia.
Explanation: ***Enterovirus*** - This patient presents with classic **viral myocarditis** progressing to **dilated cardiomyopathy**. The timeline is key: **prodromal viral illness** (fever, malaise, chest pain) a few weeks ago, followed by **progressive heart failure symptoms** over the subsequent month. - **Enteroviruses** (particularly Coxsackievirus B) are the most common cause of viral myocarditis in developed countries, accounting for 25-35% of cases. - Clinical findings of **dilated cardiomyopathy** (S3 heart sound, laterally displaced apex, bibasilar crackles, orthopnea) developing after a viral prodrome strongly support this diagnosis. - The patient's cardiovascular risk factors (HTN, hypercholesterolemia, DM) may have made him more susceptible to myocardial injury. *Cocaine use* - While cocaine can cause acute coronary syndrome, myocardial infarction, and cardiomyopathy, the **timeline does not fit**: the patient used cocaine **3 days ago** but symptoms began **1 month ago**. - Cocaine-induced cardiomyopathy typically requires **chronic use**, not a single exposure. - The cocaine use appears to be **incidental** or possibly a misguided attempt to cope with fatigue, rather than the primary etiology. *Medication side-effect* - The patient's medications (lisinopril, atorvastatin, metformin) are not associated with dilated cardiomyopathy. - **Lisinopril** is an ACE inhibitor used to *treat* heart failure, while atorvastatin and metformin have favorable or neutral cardiac profiles. *Alcohol use* - **Alcoholic cardiomyopathy** requires **chronic heavy consumption** (typically >7-8 drinks/day for >5 years). - This patient reports only **occasional alcohol use**, making this diagnosis extremely unlikely. *Bariatric surgery* - While nutritional deficiencies post-bariatric surgery can cause cardiac complications (e.g., **thiamine deficiency** leading to wet beriberi), this typically presents as **high-output heart failure** rather than the **low-output dilated cardiomyopathy** seen here. - The surgery occurred **10 years ago**, making acute nutritional deficiency less likely without other supporting evidence.
Explanation: ***Bumetanide*** - The patient presents with classic signs and symptoms of **acute decompensated heart failure** (ADHF) including progressive dyspnea, orthopnea, paroxysmal nocturnal dyspnea, recent weight gain, pitting edema, crackles, an S3 gallop, and a positive hepatojugular reflex. - **Loop diuretics** like bumetanide are the cornerstone of ADHF management due to their potent diuretic effect, which reduces **preload** by removing excess fluid and rapidly alleviates pulmonary and systemic congestion. *Nitroprusside* - This is a **venous and arterial vasodilator** used to reduce both preload and afterload in severe heart failure with elevated blood pressure or concomitant acute myocardial infarction. - While it can be used in ADHF, it is typically reserved for cases with severe hypertension or persistent congestion despite diuretics, or when an immediate reduction in afterload is critical, which is not explicitly indicated as the *best initial step* given the primary presentation of fluid overload responsive to diuresis. *Carvedilol* - **Beta-blockers** like carvedilol are essential for long-term management of chronic heart failure, improving survival and reducing hospitalizations. - However, they are generally **contraindicated or must be used with extreme caution** in the setting of acute decompensated heart failure due to their negative inotropic effects, which can worsen cardiac function and symptoms. *Milrinone* - Milrinone is a **phosphodiesterase-3 inhibitor** that provides positive inotropic effects (increasing contractility) and vasodilation. - It is typically used in patients with severe ADHF who have **low cardiac output** and are unresponsive to conventional therapy, or in those with significant renal dysfunction, but it can cause hypotension and arrhythmias. *Dopamine* - Dopamine is a **catecholamine** with dose-dependent effects; at low doses, it enhances renal perfusion, and at higher doses, it provides positive inotropic and vasopressor effects. - It is primarily used in **cardiogenic shock** or refractory hypotension associated with ADHF to support blood pressure and improve cardiac output, but its use is associated with arrhythmias and increased myocardial oxygen demand.
Explanation: ***Prolonged lung-to-brain circulation time*** - The patient's symptoms, including **paroxysmal nocturnal dyspnea (PND)** and **Cheyne-Stokes respiration (CSR)**, are characteristic of **heart failure (HF)**. In HF, a **reduced cardiac output** leads to a **prolonged lung-to-brain circulation time**. - This delay results in a lag between changes in blood gas levels at the lungs and their detection by central chemoreceptors in the brainstem, causing an **oscillatory ventilatory pattern**, where episodes of hyperpnea (over-breathing) and apnea (cessation of breathing) alternate. *Decreased central hypercapnic ventilatory responsiveness* - This would lead to **hypoventilation** and **hypercapnia (elevated CO2)**, not the alternating hyperpnea and apnea seen in **Cheyne-Stokes respiration**, which is driven by chemoreceptor instability. - While patients with **severe chronic obstructive pulmonary disease (COPD)** can have decreased hypercapnic responsiveness, it does not explain the distinct pattern of **PND** and **CSR** observed here. *Increased pulmonary artery pressure* - **Increased pulmonary artery pressure (pulmonary hypertension)** is a common consequence of **heart failure** and contributes to dyspnea. However, it does not directly explain the specific **oscillatory breathing pattern** or the sudden awakening with suffocation. - While it exacerbates respiratory symptoms, the primary mechanism of **Cheyne-Stokes respiration** relates to circulatory delay and chemoreceptor feedback. *Decreased sympathetic activity* - **Decreased sympathetic activity** would generally lead to a **slower heart rate** and **relaxation of airways**, which is contrary to the **tachycardia** (HR 126/min) and severe respiratory distress seen in the patient's presentation. - **Heart failure**, especially when decompensated, is often associated with **increased sympathetic activity** as a compensatory mechanism. *Increased partial pressure of oxygen* - An **increased partial pressure of oxygen (PaO2)** would alleviate hypoxia and improve breathing, rather than causing **dyspnea** and a complex respiratory pattern like **Cheyne-Stokes respiration**. - Patients with **heart failure** often experience **hypoxemia** due to pulmonary congestion, making an increased PaO2 an unlikely contributing factor to their respiratory distress.
Explanation: ***Correct: Furosemide*** - The patient presents with classic signs of **heart failure with fluid overload**: dyspnea on exertion, lower extremity edema, elevated jugular venous pressure, and an S3 heart sound (indicating volume overload). - **Furosemide**, a **loop diuretic**, is the most effective medication for **rapid symptomatic relief** in heart failure with congestion. It works by blocking sodium and water reabsorption in the loop of Henle, promoting diuresis and reducing **pulmonary congestion** and **peripheral edema**. - While other medications like ACE inhibitors, beta-blockers, and aldosterone antagonists are crucial for **long-term mortality reduction** and disease modification, loop diuretics provide the **fastest and most direct symptomatic improvement** for fluid overload. *Incorrect: Metoprolol* - **Metoprolol** is a **beta-blocker** that is essential for chronic HFrEF management, providing **mortality reduction** and **reverse cardiac remodeling**. - However, beta-blockers take **weeks to months** to show symptomatic benefit and can initially **worsen symptoms** due to negative inotropic effects, especially in acute decompensation. - While important for long-term management, metoprolol does not provide immediate symptomatic relief from fluid overload. *Incorrect: Losartan* - **Losartan** is an **angiotensin receptor blocker (ARB)** used as an alternative to ACE inhibitors in HFrEF, particularly in patients who develop cough with ACE inhibitors. - ARBs reduce **afterload** and prevent **cardiac remodeling**, contributing to improved long-term outcomes and mortality reduction. - However, they do not directly address fluid overload and do not provide rapid symptomatic relief compared to diuretics. *Incorrect: Spironolactone* - **Spironolactone** is an **aldosterone antagonist** that improves mortality in HFrEF by preventing myocardial fibrosis, reducing cardiac remodeling, and preventing potassium loss. - While beneficial for long-term management, spironolactone has **weak diuretic effects** and takes weeks to provide symptomatic benefit. - It is not the first-line choice for **acute symptomatic relief** of volume overload, though it is an important component of chronic HFrEF therapy. *Incorrect: Lisinopril* - **Lisinopril** is an **ACE inhibitor** and a cornerstone of HFrEF therapy, reducing **mortality**, **hospitalizations**, and preventing **cardiac remodeling** by reducing afterload and preload. - While ACE inhibitors improve symptoms over time, they do not provide the **rapid diuretic effect** needed for immediate relief of dyspnea and edema. - Lisinopril is essential for long-term management but is not the most effective option for acute symptomatic improvement of fluid overload.
Explanation: ***Tachycardia-induced cardiomyopathy secondary to atrial fibrillation*** - The patient presents with **progressively worsening dyspnea on exertion** and **fatigue**, along with signs of **heart failure** (globular cardiac shadow, prominent hila, bilateral fluffy infiltrates). - The **ECG finding of an irregularly irregular rhythm with absent P waves** is characteristic of **atrial fibrillation**, and a dilated left ventricle with an **ejection fraction of 40%** indicates **dilated cardiomyopathy**, which can be caused by chronic tachycardia in atrial fibrillation. *Acute psychological stress* - Acute psychological stress can lead to **Takotsubo cardiomyopathy** (stress-induced cardiomyopathy), which typically presents with **transient left ventricular apical ballooning** and preserved basal contractility, not necessarily a globally dilated left ventricle in this context. - While it can cause heart failure symptoms, the **chronic nature** of the symptoms (2 months) and the presence of **atrial fibrillation** make it a less likely primary cause here. *Deposition of misfolded proteins* - **Amyloidosis**, characterized by the deposition of misfolded proteins, primarily causes **restrictive cardiomyopathy**, leading to impaired diastolic filling rather than primarily systolic dysfunction with a dilated ventricle. - While amyloidosis can manifest with HF symptoms, the echocardiographic finding of a **dilated left ventricle** and the strong evidence for atrial fibrillation contributing to tachycardia-induced cardiomyopathy make this less likely. *Inherited β-myosin heavy chain mutation* - This mutation is classically associated with **hypertrophic cardiomyopathy**, characterized by **left ventricular hypertrophy** and impaired diastolic function, often with a normal or increased ejection fraction initially. - The patient's echocardiogram shows a **dilated left ventricle** with reduced ejection fraction, which is inconsistent with typical hypertrophic cardiomyopathy. *Uncontrolled essential hypertension* - Chronic uncontrolled hypertension typically leads to **hypertensive heart disease**, initially causing **left ventricular hypertrophy** and eventual **diastolic dysfunction**, before progressing to dilated cardiomyopathy in very advanced stages. - While possible, the prominent **irregularly irregular rhythm with absent P waves** guiding towards atrial fibrillation as a direct cause of tachycardia-induced cardiomyopathy makes it a more specific and likely cause in this scenario.
Explanation: ***Intravenous furosemide therapy*** - Heart failure with **preserved ejection fraction (HFpEF)** often presents with **pulmonary congestion** due to elevated filling pressures. - **Furosemide**, a loop diuretic, effectively reduces fluid overload and associated symptoms by increasing renal excretion of sodium and water. *Intravenous dobutamine* - **Dobutamine** is an inotropic agent that increases myocardial contractility and heart rate. - It is typically used for **acute decompensated heart failure with low cardiac output** and is generally avoided in HFpEF unless there is significant hypoperfusion, as it can worsen myocardial oxygen demand and diastolic dysfunction. *Intravenous morphine therapy* - **Morphine** can be used in acute heart failure to reduce preload and anxiety, but it is not a primary treatment for the underlying fluid overload. - It can cause respiratory depression and hypotension, and its use is typically reserved for patients with severe pain or dyspnea not adequately managed by other therapies. *Thoracentesis* - **Thoracentesis** is indicated for symptomatic **pleural effusions** causing respiratory distress. - While pleural effusions can occur in heart failure, initial management of generalized fluid overload typically involves diuretics, making thoracentesis a secondary intervention if diuretic therapy is insufficient. *Intermittent hemodialysis* - **Intermittent hemodialysis** is an invasive procedure primarily used for severe renal failure or refractory fluid overload that has not responded to maximal diuretic therapy. - It is not the initial step in managing heart failure with preserved ejection fraction and would only be considered in highly selected cases with **acute kidney injury** or diuretic resistance.
Explanation: ***Acute decompensated heart failure*** - The patient presents with **acute dyspnea**, **pitting edema**, **periorbital edema**, and **crackles** on lung auscultation, all consistent with **fluid overload** due to **heart failure**. - His history of **hypertension** and **diabetes mellitus** are significant risk factors, and his recent non-adherence to **lisinopril** (an ACE inhibitor) likely worsened his cardiac function, precipitating decompensation. *Acute hepatic failure* - Although **tender hepatomegaly** can be seen in acute hepatic failure, the patient's presentation is predominantly respiratory and edematous, and he has a history of *resolved* acute viral hepatitis, making acute hepatic failure less likely to be the primary cause of his *current* acute symptoms. - Acute hepatic failure would typically present with **jaundice**, **coagulopathy**, and **encephalopathy**, which are not described here. *Acute renal failure* - While **pitting edema** and **fluid overload** can occur in acute renal failure, his history of **hypertension** and **diabetes** would predispose to chronic kidney disease rather than acute renal failure as the initial presentation of his current symptoms without clear nephrotoxic exposure. - **Acute renal failure** would also likely present with significantly altered laboratory values such as elevated **creatinine** and **blood urea nitrogen**, which are not mentioned. *Pulmonary embolism* - **Dyspnea** is a key symptom of pulmonary embolism, but the extensive **edema** (periorbital, bilateral ankle, pretibial) and **crackles** are more indicative of fluid overload than a primary thromboembolic event. - Though his pulse is elevated, there are no other classic signs of PE such as **pleuritic chest pain**, **hemoptysis**, or a history of **deep vein thrombosis**. *Diabetic ketoacidosis* - While the patient has diabetes and recent medication non-adherence, this condition is characterized by **hyperglycemia**, **metabolic acidosis**, and **ketonuria**, typically presenting with **Kussmaul respirations** and **abdominal pain**. - The patient's symptoms of significant fluid overload and respiratory distress with crackles are not typical of DKA.
Explanation: ***Continue with an ultrasound-guided biopsy of the transplanted kidney*** - The patient's symptoms (fever, malaise, abdominal pain, rising creatinine) and ultrasound findings (fluid collection, hydronephrosis) are highly suggestive of **acute renal allograft rejection** or an **obstructive uropathy**, necessitating a definitive diagnosis through biopsy. - A biopsy will differentiate between rejection, drug toxicity, or other causes of allograft dysfunction, guiding appropriate and specific treatment. *Re-operate and remove the failed kidney transplant* - Removing the transplanted kidney is a drastic measure and premature at this stage, as the cause of dysfunction is not yet confirmed. - The elevated creatinine and hydronephrosis could be reversible with proper treatment once the underlying cause is identified. *Start on pulse steroid treatment or OKT3* - While pulse steroids or OKT3 (muromonab-CD3) are used to treat acute rejection, administering them without a definitive diagnosis from a biopsy could be inappropriate and potentially harmful. - The symptoms could also be due to infection or obstruction, which would not respond to these immunosuppressive therapies and could worsen with increased immunosuppression. *Supportive treatment with IV fluids, antibiotics, and antipyretics* - Supportive care alone is insufficient given the potential for acute allograft rejection or severe obstruction, which requires specific intervention. - Although the patient has fever, there are no clear signs of infection, and empirical antibiotics may delay necessary diagnostic steps. *Consider hemodialysis* - While the patient's creatinine is elevated and potassium is high, these parameters alone do not immediately warrant hemodialysis without exploring the underlying cause of allograft dysfunction. - Dialysis is typically considered when there are severe indications like refractory hyperkalemia, fluid overload, acidosis, or uremic symptoms that cannot be otherwise managed, and the primary goal should be to treat the cause of decreasing kidney function.
Explanation: **Impaired myocardial relaxation** - The patient's symptoms of nocturnal dyspnea, frothy sputum, and bibasilar crackles, coupled with a **preserved ejection fraction (55%)**, are highly suggestive of **diastolic heart failure**. The isolated **S4 heart sound** at the apex further points to a stiff, non-compliant left ventricle. - **Long-standing hypertension** commonly leads to left ventricular hypertrophy and impaired relaxation, and the history of **Paget disease of bone** may also contribute to high-output states and myocardial stiffness, although diastolic dysfunction is a more direct consequence of the hypertrophy from hypertension. *Diuretic overdose* - Diuretic overdose would typically present with symptoms of **dehydration** and electrolyte abnormalities, such as hypokalemia or hyponatremia. - While diuretics can be used to treat heart failure symptoms, an overdose would not explain the specific cardiac findings like an **S4 heart sound** or the underlying pathophysiology of heart failure with preserved ejection fraction. *Systemic arteriovenous fistulas* - Systemic arteriovenous fistulas can cause **high-output heart failure** due to increased venous return, but this usually manifests as a wide pulse pressure and signs of hyperdynamic circulation. - They are less likely to cause isolated diastolic dysfunction with a preserved ejection fraction and a prominent **S4 heart sound**. *Destruction of alveolar walls* - Destruction of alveolar walls is characteristic of **emphysema**, a form of chronic obstructive pulmonary disease (COPD). - While the patient has a smoking history and cough, the primary presentation with paroxysmal nocturnal dyspnea, frothy sputum, and bibasilar crackles, along with a prominent **S4 heart sound**, points more specifically to a cardiac etiology rather than isolated COPD. *Decreased myocardial contractility* - **Decreased myocardial contractility** would lead to **systolic heart failure**, characterized by a **reduced left ventricular ejection fraction**. - The patient's ejection fraction is preserved at 55%, ruling out systolic dysfunction as the primary cause of his symptoms.
Explanation: ***Left-sided heart failure*** - The patient's inability to breathe while lying flat (orthopnea) and the relief obtained by elevating his head with pillows is a classic symptom of **left-sided heart failure**. - In this condition, accumulation of fluid in the lungs (pulmonary congestion) due to the heart's inability to pump blood effectively leads to difficulty breathing, especially in the recumbent position. *Amyotrophic lateral sclerosis (ALS)* - ALS primarily affects **motor neurons**, leading to progressive muscle weakness, atrophy, and spasticity. - While it can eventually cause respiratory muscle weakness, it typically presents with more generalized motor symptoms and does not specifically manifest as acute orthopnea relieved by elevating the head of the bed shortly after lying down. *Obstructive sleep apnea* - Obstructive sleep apnea is characterized by recurrent upper airway collapse during sleep, leading to **pauses in breathing** and loud snoring. - While it can cause fragmented sleep and daytime sleepiness, the primary relief is not typically from simply adding pillows but rather from CPAP therapy or surgical interventions to open the airway. *Right-sided heart failure* - Right-sided heart failure primarily leads to **systemic venous congestion**, causing symptoms like peripheral edema, ascites, and jugular venous distension. - It does not typically cause orthopnea as a primary symptom, as pulmonary congestion is not the predominant feature. *Myasthenia gravis* - Myasthenia gravis is an **autoimmune disorder** characterized by fluctuating weakness of voluntary muscles, which worsens with activity and improves with rest. - While it can affect respiratory muscles in severe cases, leading to respiratory compromise, the symptom presentation is more varied than isolated orthopnea, and it does not typically manifest acutely only when lying flat to sleep.
Explanation: ***Volume depletion*** - The patient's presentation with **elevated BUN** and **creatinine**, along with **high urine osmolality** (600 mOsm/kg) and **low urine sodium** (10 mEq/L), are classic signs of **prerenal azotemia**, indicating effective circulating volume depletion. - The patient has **congestive heart failure exacerbation**, which is often treated with **diuretics**, and a history of **ibuprofen** use, both of which can contribute to volume depletion and impaired renal perfusion. *Antibiotic use* - While **amikacin** is nephrotoxic, the urinalysis findings (**high urine osmolality**, **low urine sodium**) are not typical of established acute kidney injury (e.g., acute tubular necrosis) caused by aminoglycosides, which generally cause an inability to concentrate urine and higher urine sodium due to tubular damage. - The timing of the renal insufficiency, occurring 4 days after starting CHF treatment and after completing amikacin, points away from amikacin as the primary, immediate cause. *Glomerulonephritis* - **Glomerulonephritis** typically presents with active urine sediment (e.g., **red blood cell casts**, **proteinuria**), which is not mentioned here. - The urine osmolality and sodium values are not characteristic of glomerulonephritis, which is a cause of intrinsic renal disease. *Urinary tract infection* - A **urinary tract infection (UTI)** primarily causes symptoms like dysuria, frequency, and urgency, and can lead to pyelonephritis with fever and flank pain. - While UTIs can worsen renal function, they do not directly explain the specific laboratory findings of **prerenal azotemia**. *Bladder outlet obstruction* - **Bladder outlet obstruction** (due to **benign prostatic hyperplasia** in this patient) causes **postrenal azotemia**, which would typically manifest with **bilateral hydronephrosis** on imaging and often leads to an inability to concentrate urine effectively over time, with less dramatic changes in urine sodium initially. - The given urine osmolality and sodium values are very suggestive of prerenal causes, not obstruction.
Explanation: ***↓ ↑ normal normal*** - Doxorubicin is an **anthracycline** known to cause **dilated cardiomyopathy**, characterized by **decreased ventricular wall thickness**, **increased ventricular cavity size**, and **preserved diastolic function**. - The S3 gallop and pitting edema indicate **heart failure with reduced ejection fraction (HFrEF)**, consistent with dilated cardiomyopathy. *Normal normal ↓ normal* - This option suggests a primary issue with **diastolic function**, which is not the typical presentation of doxorubicin-induced cardiomyopathy. - While diastolic dysfunction can occur, doxorubicin characteristically causes **systolic dysfunction** manifesting as chamber dilation and wall thinning. *↑ ↓ ↓ normal* - This pattern of **increased wall thickness** and **decreased cavity size** is characteristic of **hypertrophic cardiomyopathy** or **restrictive cardiomyopathy**, which are generally not caused by doxorubicin. - Doxorubicin typically causes **cardiac muscle fiber damage** leading to thinning and dilation. *↑ ↓ ↓ ↑* - This option also suggests **increased wall thickness** and **decreased cavity size**, inconsistent with doxorubicin's effects on the heart. - The **elevated aorto-ventricular pressure gradient** might indicate outflow tract obstruction or significant aortic stenosis, which are not typical sequelae of doxorubicin. *↓ ↑ ↓ normal* - While doxorubicin leads to **decreased wall thickness** and **increased cavity size**, the diastolic function is usually preserved early on, not decreased. - A decrease in diastolic function might occur in later stages, but the primary and most characteristic feature due to doxorubicin is **systolic dysfunction** and chamber remodeling.
Explanation: ***Pulmonary edema*** - This patient's **hypertension** and **diabetes** are major risk factors for heart failure, and the acute onset of **shortness of breath** with **tachypnea** suggests cardiogenic pulmonary edema. - **Decreased tidal volume** occurs because fluid accumulation in the interstitium and alveoli reduces functional lung capacity, prompting rapid, shallow breathing to maintain minute ventilation. - While pulmonary edema typically causes **decreased lung compliance** due to fluid-stiffened lungs, early or mild cases may show relatively preserved compliance, or the normal compliance here may reflect measurement timing or technique. The clinical picture and decreased tidal volume strongly support pulmonary edema. - The combination of cardiac risk factors, acute dyspnea, tachypnea, and altered breathing pattern make this the most likely diagnosis. *Diabetic ketoacidosis* - DKA causes **Kussmaul respirations** (deep, labored breathing) to compensate for metabolic acidosis, not the shallow breathing pattern (decreased tidal volume) seen here. - DKA typically presents with polyuria, polydipsia, abdominal pain, nausea, and fruity breath odor, which are not mentioned. - While this patient has diabetes, the respiratory pattern and absence of typical DKA symptoms make this less likely. *Rib fracture* - Rib fractures cause **pleuritic chest pain** that worsens with breathing, leading to voluntary splinting and reduced tidal volume. - However, there is **no history of trauma** or chest pain reported. - Pain from rib fractures would be localized, and the acute 2-day onset of dyspnea without trauma makes this unlikely. *Emphysema exacerbation* - Emphysema is characterized by **increased lung compliance** (hyperinflation) due to alveolar wall destruction, which contradicts the normal compliance finding. - While the patient has a significant smoking history, the **normal lung compliance** argues against emphysema. - COPD exacerbations typically present with wheezing, productive cough, and hyperinflation, not decreased tidal volume with normal compliance. *Tension pneumothorax* - Tension pneumothorax presents with **severe respiratory distress**, unilateral absent breath sounds, **hypotension**, tracheal deviation, and jugular venous distension. - This patient's **blood pressure is normal** (138/75 mm Hg) and there's no mention of absent breath sounds or hemodynamic compromise. - The clinical presentation does not support this life-threatening emergency.
Explanation: ***Normal perfusion with bilateral ventilation defects*** - The patient's presentation with **worsening shortness of breath** after an acute coronary event, along with chest x-ray findings of **distended pulmonary veins, Kerley B lines (small horizontal lines at the lung bases), and blunting of the costophrenic angles**, is highly suggestive of **pulmonary edema** due to heart failure. - In pulmonary edema, the alveoli fill with fluid, impeding gas exchange. This leads to **impaired ventilation** in the affected areas, while **pulmonary blood flow (perfusion) remains intact**. This results in **ventilation-perfusion (V/Q) mismatch** with impaired ventilation. *Matched ventilation and perfusion bilaterally* - This pattern would indicate a **normal ventilation-perfusion scan**, which is inconsistent with the patient's severe shortness of breath, hypoxemia, and radiographic signs of pulmonary edema. - A matched V/Q scan suggests **healthy lung function** and gas exchange. *Normal ventilation with multiple, bilateral perfusion defects* - This pattern is characteristic of **pulmonary embolism**, where blood clots obstruct pulmonary arteries, leading to areas of the lung being ventilated but not perfused. - The clinical picture and chest x-ray findings in this patient are not consistent with pulmonary embolism. *Normal perfusion with decreased ventilation at the right base* - While a focal ventilation defect could occur, the patient's symptoms and chest x-ray findings (distended pulmonary veins, Kerley B lines, bilateral blunting of costophrenic angles) suggest **generalized rather than localized pulmonary edema**. - This option describes a unilateral and focal issue, whereas heart failure typically causes bilateral findings. *Increased apical ventilation with normal perfusion bilaterally* - This finding is not typical in any common pulmonary pathology. Increased apical ventilation is not a characteristic of pulmonary edema or other V/Q mismatch disorders. - This scenario does not align with the patient's symptoms or imaging findings.
Explanation: ***Furosemide*** - The patient presents with classic signs of **acute decompensated heart failure**, including **dyspnea, orthopnea, bilateral rales, and pitting edema**. This indicates **volume overload**. - **Furosemide**, a loop diuretic, is the most appropriate initial therapy to rapidly reduce fluid overload, alleviate symptoms, and improve cardiac function. *Hyperoncotic starch* - **Hyperoncotic starch** is a colloid solution used for **volume expansion** in cases of hypovolemia or shock. - Administering a volume expander to a patient with **fluid overload due to heart failure** would worsen their condition. *Terlipressin* - **Terlipressin** is a **vasopressin analog** primarily used in the management of **hepatorenal syndrome** and **esophageal variceal bleeding**. - It is not indicated for the treatment of **acute decompensated heart failure** or fluid overload. *Normal saline* - **Normal saline** is an **isotonic crystalloid solution** used for volume resuscitation in hypovolemic states. - Providing additional fluids to a patient already in **fluid overload** would exacerbate fluid retention and worsen heart failure symptoms. *Norepinephrine* - **Norepinephrine** is a **vasopressor** used to increase blood pressure in patients with **hypotensive shock**. - While the patient's blood pressure is on the lower side (108/60 mmHg), immediate **volume reduction** with diuretics is paramount for heart failure, not vasopressor support unless overt cardiogenic shock develops.
Explanation: ***Decreased cardiac contractility due to cardiac myocyte injury*** - The patient presents with **myocarditis** following a viral infection (positive Coxsackie B antibody), leading to inflammation and injury of cardiac myocytes. This results in **decreased cardiac contractility**, significantly reducing the **ejection fraction (30%)** and causing **heart failure** symptoms like pedal edema, jugular venous distension, and difficulty sleeping due to orthopnea and paroxysmal nocturnal dyspnea, which are common in heart failure. - The **elevated troponins** and **CK-MB** confirm cardiac myocyte injury, and the ECG findings of diffuse ST-segment elevation and PR-segment depression are classic for **pericarditis**, which often coexists with or results from myocarditis, contributing to the chest pain and overall cardiac dysfunction. *Impaired gaseous exchange caused by pulmonary edema* - While **pulmonary edema** can impair gaseous exchange and cause difficulty sleeping, the chest X-ray in this case shows **clear lung fields**, suggesting that significant pulmonary edema is not the primary mechanism. - The **oxygen saturation is 98%**, indicating adequate oxygenation despite the heart failure, so impaired gaseous exchange is not the direct cause of sleeplessness. *Progressive cardiac ischemia caused by a plaque event* - The patient's presentation with a preceding **viral illness**, diffuse ST-segment elevation, and **positive Coxsackie B antibodies** points towards **inflammatory conditions** like myocarditis and pericarditis, rather than an ischemic event due to a plaque rupture. - There is no mention of **risk factors for coronary artery disease**, and the chest pain characteristics are more consistent with pericarditis (sharp, intermittent, worsening with exertion) than with typical angina from a plaque event. *Lobar consolidation due to Staphylococcus aureus* - **Lobar consolidation** due to *Staphylococcus aureus* would typically present with symptoms of **pneumonia**, such as productive cough, dyspnea, and focal lung findings on examination and chest X-ray, none of which are described. - The chest X-ray shows **clear lung fields**, ruling out lobar consolidation as the cause of the patient's symptoms. *Diffuse alveolar damage and hyaline membrane formation* - **Diffuse alveolar damage** and **hyaline membrane formation** are characteristic features of **Acute Respiratory Distress Syndrome (ARDS)**, which would manifest as severe hypoxemia and diffuse bilateral infiltrates on chest X-ray. - This patient has **clear lung fields** and **normal oxygen saturation**, making ARDS an unlikely diagnosis.
Explanation: ***Decrease total peripheral resistance*** - The patient presents with symptoms and signs consistent with **mitral regurgitation (MR)** and **heart failure (HF)**, likely secondary to **rheumatic heart disease** (history of recurrent sore throats). The low ejection fraction (25%) indicates **systolic dysfunction**. - Decreasing **total peripheral resistance (TPR)** (afterload) reduces the resistance against which the left ventricle must pump, thereby increasing **forward flow** into the aorta and reducing the regurgitant volume into the left atrium through the incompetent mitral valve. This improves cardiac output and reduces symptoms of heart failure. *Increase coronary blood flow* - While increased coronary blood flow is always beneficial for cardiac function, the primary problem in this patient is **valvular heart disease** leading to volume overload and systolic dysfunction, not primarily **coronary artery disease**. - Addressing coronary perfusion would not directly resolve the immediate hemodynamic burden imposed by severe mitral regurgitation and heart failure. *Increase inotropy of cardiac muscle* - **Positive inotropes** increase the force of myocardial contraction and might initially seem helpful given the low ejection fraction. However, in pure MR, increasing contractility can **worsen regurgitation** by increasing the pressure gradient across the incompetent valve. - The goal in MR is to reduce **afterload** to promote forward flow, not necessarily to increase the force of contraction against a leaking valve. *Increase left ventricular end diastolic pressure* - An **increased left ventricular end-diastolic pressure (LVEDP)** is indicative of **volume overload** and **heart failure**, and it is a pathological finding, not a therapeutic goal. - Therapeutic interventions aim to decrease LVEDP by reducing preload and/or improving cardiac output, thereby alleviating congestion. *Increase the rate of SA node discharge* - Increasing the **heart rate** (SA node discharge) in a patient with heart failure and MR would be detrimental as it **reduces diastolic filling time**, further decreasing cardiac output, and **increases myocardial oxygen demand**. - Tachycardia would worsen symptoms and contribute to ventricular dysfunction rather than improving it.
Explanation: ***Leukocyte esterase positive*** - This patient is experiencing a possible **drug-induced interstitial nephritis**, likely due to **furosemide**, given the new onset **eosinophilia**, rising creatinine, and exposure to a new medication. - **Leukocyte esterase** detects WBCs in the urine, which are characteristic of interstitial nephritis due to inflammation in the renal interstitium. *Nitrites positive* - **Nitrites** are typically positive in **bacterial urinary tract infections (UTIs)**, indicating the presence of nitrate-reducing bacteria. - The clinical picture of **eosinophilia** and **acute kidney injury** makes a primary UTI less likely in this case. *Bacteria > 100 CFU/mL* - A high **bacterial colony count** is a hallmark of a **bacterial urinary tract infection**, but the patient's symptoms are more consistent with drug-induced kidney injury, not infection. - The presence of **eosinophilia** and **elevated creatinine** further points away from a straightforward UTI as the primary issue. *Crystals* - **Crystals** in the urine can indicate conditions like **nephrolithiasis** (kidney stones) or certain metabolic disorders, but they do not explain the patient's acute kidney injury with eosinophilia. - This finding would not align with the suspected diagnosis of **drug-induced interstitial nephritis**. *Red blood cell casts* - **Red blood cell casts** are highly indicative of **glomerulonephritis**, suggesting direct damage to the glomeruli. - While acute kidney injury is present, the associated **eosinophilia** and recent medication change are more characteristic of acute interstitial nephritis, not glomerulonephritis.
Explanation: ***Diuretic therapy*** - The patient's initial presentation is consistent with **acute decompensated heart failure**, characterized by shortness of breath, orthopnea, lower limb edema, rales, S3 gallop, and a holosystolic murmur (likely mitral regurgitation due to ventricle dilation). The initial normal kidney function (BUN 20, creatinine 0.8) and electrolyte values support acute heart failure. - The subsequent drop in blood pressure (155/92 to 110/60 mmHg), increase in heart rate (102 to 110/min), and significant rises in BUN (20 to 45 mg/dL) and creatinine (0.8 to 1.7 mg/dL) with a decrease in potassium (4.2 to 3.2 mEq/L) strongly suggest **diuretic-induced volume depletion** leading to worsened renal function (prerenal azotemia) and hypokalemia. *Urinary tract obstruction* - This would typically present with symptoms like **dysuria**, frequency, or hesitancy, and acute kidney injury with a more prominent rise in creatinine relative to BUN, none of which are described. - Obstruction would be less likely to cause a significant drop in blood pressure and hypokalemia, as seen in this patient. *Chronic renal failure* - While kidney function has worsened, the initial labs showed normal kidney function, ruling out **chronic disease** as the cause of the acute deterioration. - Chronic renal failure would typically present with elevated BUN and creatinine for an extended period, which is not the case here. *Glomerular basement membrane damage* - Conditions involving **glomerular damage**, such as glomerulonephritis, typically present with proteinuria, hematuria, and often hypertension, which are not detailed in this scenario. - The acute changes in electrolytes and BUN/creatinine are more indicative of a **hemodynamic issue** rather than a primary glomerular pathology. *Cholesterol emboli* - While a patient with a history of CABG is at risk for **cholesterol emboli**, this condition typically causes acute kidney injury, livedo reticularis, eosinophilia, and digital ischemia, which are not described. - It would not explain the rapid electrolyte shifts and clear signs of volume depletion seen in this patient.
Explanation: **A 56-year-old male with NYHA class III heart failure with an LVEF of 32%, currently taking lisinopril, furosemide, and digoxin** - This patient perfectly matches the **inclusion criteria** of the RALES trial: **NYHA class III or IV heart failure**, **LVEF ≤ 35%**, and current treatment with an **ACE inhibitor (lisinopril)**, a **loop diuretic (furosemide)**, and **digoxin**. - The study's findings regarding spironolactone's benefits are directly applicable to such a patient, as they meet all the **demographic and clinical characteristics** of the study population. *An 82-year-old female with NYHA class II heart failure with an LVEF of 22%, taking lisinopril, furosemide, and digoxin* - This patient has **NYHA class II heart failure**, which is **less severe** than the inclusion criteria of **NYHA class III or IV** in the study. - While other criteria (LVEF, medication regimen) are met, the **lower NYHA class** means the direct applicability of the study's findings might be limited, as the benefits might not be as pronounced in less severe heart failure. *An 86-year-old female recently found to have an LVEF of 34%, currently taking furosemide and carvedilol* - This patient is not taking an **ACE inhibitor** (like lisinopril), which was a required background medication for all participants in the RALES trial. - While carvedilol (a beta-blocker) is also crucial in heart failure management, the study specifically investigated spironolactone as an add-on to an **ACE inhibitor-based regimen**. *A 78-year-old male with NYHA class II heart failure and LVEF 36%* - This patient has **NYHA class II heart failure**, which is **less severe** than the study's inclusion criteria of **NYHA class III or IV**. - Additionally, his **LVEF of 36%** is above the study's threshold of **≤ 35%**, making him ineligible for direct application of these results. *A 65-year-old male with newly diagnosed NYHA class IV heart failure and a LVEF of 21%, about to begin medical therapy* - This patient has **newly diagnosed heart failure** and has not yet started the **background medical therapy** (ACE inhibitor, loop diuretic, digoxin) that all study participants were already receiving. - The trial evaluated spironolactone as an **add-on therapy** to existing standard care, not as initial therapy for newly diagnosed heart failure patients.
Explanation: ***Vitamin B1 deficiency*** - The patient exhibits symptoms of **dilated cardiomyopathy (DCM)**, including progressive dyspnea, decreased exercise tolerance, orthopnea, and a gallop rhythm. **Vitamin B1 deficiency** (beriberi) is a known cause of **high-output cardiac failure**, which can lead to DCM. - The patient's history of **heroin and cocaine use** and **homelessness** puts him at high risk for nutritional deficiencies, including thiamine (Vitamin B1). *Myosin mutation* - **Myosin mutations** are a common cause of **hypertrophic cardiomyopathy (HCM)**, not dilated cardiomyopathy. - HCM is characterized by a **thickened ventricular wall** and impaired diastolic filling, not primarily ventricular dilation as suggested by the patient's symptoms. *Turner syndrome* - Turner syndrome is associated with **coarctation of the aorta** and **bicuspid aortic valve**, but not typically dilated cardiomyopathy. - These conditions can lead to cardiovascular complications but present differently than the patient's symptoms. *Amyloid production* - **Amyloidosis** commonly causes **restrictive cardiomyopathy**, characterized by **stiffening of the ventricular walls** and impaired diastolic filling, leading to symptoms of heart failure. - While amyloid can affect the heart, it typically presents with a non-dilated, stiff heart rather than the ventricular dilation seen in DCM. *Radiation therapy* - **Radiation therapy** to the chest can cause **restrictive cardiomyopathy**, **pericardial disease**, or **coronary artery disease**. - It is not a common cause of dilated cardiomyopathy presenting with this specific clinical picture and risk factors.
Explanation: ***Lymphocytic infiltration*** - The patient's presentation with **heart failure symptoms** (shortness of breath, edema, S3 gallop, displaced PMI) preceded by a **viral-like illness** (fever, malaise, myalgias) is highly suggestive of **acute myocarditis**. - **Lymphocytic infiltration** is the hallmark histological finding in **viral myocarditis**, where **cytotoxic T-lymphocytes** attack virally infected cardiomyocytes. *Eosinophilic infiltration* - **Eosinophilic myocarditis** is a distinct form of myocarditis often associated with **hypersensitivity reactions** (e.g., drug-induced, parasitic infections, autoimmune conditions). - While it can cause heart failure, the preceding viral-like illness is less characteristic, and eosinophils would be prominent histologically. *Giant cell infiltration* - **Giant cell myocarditis** is a rare, aggressive form of myocarditis characterized by **multinucleated giant cells** and **extensive necrosis**. - It typically presents with rapid onset, severe heart failure, and often requires urgent transplantation, and is not typically preceded by a simple viral prodrome. *Granulomatous infiltration* - **Granulomatous inflammation** in the heart is seen in conditions like **sarcoidosis** or **tuberculosis**. - While these can cause heart failure, the clinical picture here is not typical for **cardiac sarcoidosis** (which often presents with conduction abnormalities) or active tuberculosis. *Fibrosis and calcification* - **Fibrosis and calcification** represent chronic or healed myocardial injury rather than an acute inflammatory process. - While these can lead to heart failure (e.g., in dilated cardiomyopathy), they are the end-stage consequences of disease, not the initial cellular infiltration explaining acute myocarditis.
Explanation: ***Smoking cessation*** - This patient's symptoms (progressive shortness of breath, cough, end-expiratory wheezing) and PFT results (reduced FEV1, reduced FEV1:FVC ratio, normal TLC) are highly suggestive of **COPD**, which is primarily caused by smoking. - **Smoking cessation** is the only intervention clearly shown to slow the rate of FEV1 decline in patients with COPD, thereby improving long-term prognosis. *Salmeterol therapy* - **Salmeterol** is a long-acting beta-agonist (LABA) that provides bronchodilation and symptom relief in COPD. - While it improves symptoms and quality of life, it does **not alter the natural history of the disease** or slow the decline in FEV1. *Fluticasone therapy* - **Fluticasone** is an inhaled corticosteroid (ICS) used in COPD, often in combination with LABAs, particularly for patients with frequent exacerbations. - ICS therapy can reduce exacerbations but does **not slow the FEV1 decline** in COPD and may increase the risk of pneumonia. *Alpha-1 antitrypsin therapy* - **Alpha-1 antitrypsin deficiency** is a genetic cause of emphysema, typically presenting at a younger age or with a strong family history. This patient's history does not directly point to this diagnosis. - While augmentation therapy with alpha-1 antitrypsin can slow lung function decline in genetically deficient individuals, it is **ineffective for typical smoking-induced COPD**. *Breathing exercises* - **Breathing exercises**, such as pursed-lip breathing, are components of pulmonary rehabilitation programs. - They can improve symptoms, exercise tolerance, and quality of life but do **not impact the underlying disease progression** or FEV1 decline in COPD.
Explanation: ***Left heart failure*** - **Bibasilar crackles** and **wheezing** ("cardiac asthma") in an elderly patient, combined with **rust-colored sputum**, are classic signs of **pulmonary edema** due to acute decompensated left heart failure. - The rust color of the sputum can indicate the presence of **hemosiderin-laden macrophages** (heart failure cells), which result from chronic pulmonary congestion. *Tall, thin males* - This patient demographic is primarily associated with **spontaneous pneumothorax**, which presents as sudden onset chest pain and shortness of breath, not bibasilar crackles or rust-colored sputum. - While spontaneous pneumothorax can cause respiratory distress, the other findings do not align with this condition. *Protein C/S deficiency* - Deficiencies in Protein C or S are inherited thrombophilias that increase the risk of **venous thromboembolism**, including **pulmonary embolism**. - While a pulmonary embolism can cause respiratory symptoms, it is less likely to present with bibasilar crackles and rust-colored sputum in this manner without other signs of acute embolization. *Long bone fractures* - **Long bone fractures** are a significant risk factor for **fat embolism syndrome**, which can cause respiratory distress, neurological symptoms, and a petechial rash. - However, the patient's presentation with bibasilar crackles, wheezing, and rust-colored sputum is not typical for fat embolism syndrome, and there is no history of trauma. *Smoking* - While smoking is a major risk factor for many respiratory diseases like **COPD** and **lung cancer**, it does not directly cause the acute presentation of bibasilar crackles, wheezing, and rust-colored sputum in the same way as left heart failure. - COPD typically involves chronic cough, sputum production (often clear or white), and wheezing, but not typically rust-colored sputum indicative of acute pulmonary edema.
Explanation: **Spironolactone, in addition to standard therapy, substantially reduces the risk of morbidity and death in patients with severe heart failure** - The trial showed a **30% reduction in the risk of death** and a **35% lower frequency of hospitalization** for worsening heart failure in the spironolactone group (morbidity). - Patients receiving spironolactone also had a **significant improvement in heart failure symptoms**, as assessed by the NYHA functional class. *The incidence of both gynecomastia and hyperkalemia was elevated in patients treated with spironolactone* - While **gynecomastia was elevated** (10% vs 1%), the incidence of **serious hyperkalemia was minimal** in both groups, contradicting the statement that hyperkalemia was elevated. - The text explicitly states, "The incidence of serious hyperkalemia was minimal in both groups of patients." *Spironolactone did not improve all-cause morbidity and mortality in patients with severe heart failure* - This statement is **directly contradicted by the results**, which showed a significant reduction in all-cause mortality (30%) and improved morbidity (35% lower hospitalization, improved symptoms). - The trial was, in fact, "discontinued early... because an interim analysis determined that spironolactone was efficacious." *Given the large sample size of this clinical trial, the results are likely generalizable to all patients with heart failure* - The study specifically enrolled patients with **severe heart failure** (ejection fraction ≤ 35%) who were already on **standard therapy** (ACE inhibitor, loop diuretic, digoxin). - Therefore, the results are generalizable to this specific subgroup of severe heart failure patients, not necessarily *all* patients with heart failure. *The addition of spironolactone significantly improved symptoms of heart failure, but not overall mortality* - This statement is **incorrect** as the trial explicitly reported a **30% reduction in the risk of all-cause death** in the spironolactone group (mortality). - Additionally, it did show improvement in symptoms, meaning the first part of the statement is true, but the latter part regarding mortality is false.
Explanation: ***Heart failure*** - This patient's presentation with progressive ataxia, nystagmus, dysarthria, kyphoscoliosis, foot deformities, sensory deficits, and decreased deep tendon reflexes is highly suggestive of **Friedreich ataxia**. - **Cardiomyopathy** and **congestive heart failure** are the leading causes of death in patients with Friedreich ataxia, affecting approximately 60% of patients and often leading to premature mortality. *Aspiration pneumonia* - While patients with **neurological deficits** like dysarthria and ataxia are at increased risk for aspiration, it is not the most common or direct cause of death in Friedreich ataxia compared to cardiac complications. - Aspiration pneumonia is a serious complication, but **cardiac involvement** typically dictates the prognosis and survival in this condition. *Leukemia* - There is **no established link** between Friedreich ataxia and an increased risk of developing leukemia. - The patient's symptoms are characteristic of a primary neurological and systemic disorder, not a hematological malignancy. *Renal cell carcinoma* - This type of cancer is **not associated** with Friedreich ataxia. - The presented symptoms do not point towards any renal pathology or an increased risk for renal cell carcinoma. *Posterior fossa tumors* - While the mother had a vestibular schwannoma, which is a **posterior fossa tumor**, the patient's symptoms are not consistent with a tumor of the posterior fossa. - The **progressive, diffuse neurological deficits** affecting both motor and sensory systems, along with systemic manifestations like kyphoscoliosis, are characteristic of a genetic ataxia rather than a focal tumor.
Explanation: ***Congestive heart failure*** - The **pleural fluid to serum protein ratio of 0.35** and **LDH ratio of 0.49** fall within the criteria for a **transudative effusion** (ratios < 0.5 for protein and < 0.6 for LDH). - **Congestive heart failure (CHF)** is a common cause of transudative pleural effusions due to increased hydrostatic pressure. *Uremia* - **Uremic pleuritis** typically causes an **exudative effusion**, characterized by higher protein and LDH levels in the pleural fluid. - While patients with uremia may have pleural effusions, the fluid analysis here is not consistent with that diagnosis. *Chylothorax* - A **chylothorax** is characterized by a **milky-white fluid** with very high triglyceride levels (>110 mg/dL), resulting from lymphatic leakage. - The described fluid is "light pink" and does not have the typical biochemical profile of a chylothorax. *Pancreatitis* - **Pancreatitis-induced pleural effusions** are almost always **exudative** and typically have **elevated amylase levels**. - The transudative nature of the effusion rules out pancreatitis as the most likely cause. *Sarcoidosis* - **Sarcoidosis** can cause **pleural effusions**, but these are usually **exudative** and often accompanied by other systemic manifestations like lymphadenopathy or skin lesions. - The presented fluid analysis does not support a diagnosis of sarcoidosis.
Explanation: ***Pneumothorax*** - The patient's presentation with **worsening shortness of breath**, **increased anteroposterior diameter**, **diminished breath sounds**, and **basilar-predominant bullous changes** strongly suggests **Alpha-1 antitrypsin deficiency** (AATD) which causes panacinar emphysema. - Patients with severe emphysema, particularly those with **large bullae**, are at significantly increased risk of developing a **spontaneous pneumothorax** due to the rupture of these fragile air sacs. *Bronchogenic carcinoma* - While smoking is a major risk factor for **bronchogenic carcinoma**, this patient has **never smoked**, making it less likely given his current symptoms. - The imaging findings of **bullous changes** are more indicative of emphysema than neoplastic changes. *Pulmonary fibrosis* - **Pulmonary fibrosis** typically presents with a **restrictive lung disease pattern**, characterized by decreased lung volumes and often reticular changes on imaging. - The patient's findings, such as an **increased anteroposterior diameter** and **flattened diaphragm**, are characteristic of **obstructive lung disease** (emphysema), not fibrosis. *Bronchiolitis obliterans* - **Bronchiolitis obliterans** is a rare obstructive lung disease often associated with **post-infectious sequelae**, connective tissue diseases, or following lung transplantation. - The clinical and radiological findings are more consistent with **emphysema** due to Alpha-1 antitrypsin deficiency, rather than bronchiolitis obliterans. *Churg-Strauss syndrome* - **Churg-Strauss syndrome** (eosinophilic granulomatosis with polyangiitis) is a systemic vasculitis characterized by **asthma**, **eosinophilia**, and **extrapulmonary involvement**. - While asthma can cause wheezing, the predominant radiological findings of **bullous emphysema** and the risk factors for pulmonary collapse are inconsistent with Churg-Strauss syndrome.
Explanation: ***Increased serum hematocrit*** - This patient presents with symptoms highly suggestive of **chronic bronchitis**, a form of COPD, characterized by a **chronic productive cough** and **hypoxemia**. - **Chronic hypoxemia** stimulates the kidneys to release **erythropoietin**, leading to secondary **polycythemia** (increased red blood cell mass) and thus an **increased hematocrit** to improve oxygen-carrying capacity. *Increased FEV1/FVC ratio* - This patient's symptoms (shortness of breath, productive cough, wheezing, smoking history) are classic for **chronic obstructive pulmonary disease (COPD)**, which is an **obstructive lung disease**. - Obstructive lung diseases are characterized by **decreased FEV1/FVC ratio** due to airflow limitation, not an increased ratio. *Increased diffusing capacity for carbon monoxide* - In COPD, particularly chronic bronchitis and emphysema, the **diffusing capacity for carbon monoxide (DLCO)** is typically **decreased** due to destruction of alveolar-capillary membranes (emphysema) and ventilation-perfusion mismatch (chronic bronchitis). - An increased DLCO is more commonly seen in conditions like **pulmonary hemorrhage** or **asthma**. *Increased pulmonary capillary wedge pressure* - **Increased pulmonary capillary wedge pressure (PCWP)** is characteristic of **left-sided heart failure**, indicating elevated left atrial and pulmonary venous pressures. - While patients with severe COPD can develop **pulmonary hypertension** and eventually **right-sided heart failure (cor pulmonale)**, the primary pathology described here points to lung disease, not left ventricular dysfunction. *Normal FEV1* - In COPD, there is **airflow obstruction** that manifests as a **reduced forced expiratory volume in 1 second (FEV1)**. - A normal FEV1 would be inconsistent with the clinical presentation of significant, worsening shortness of breath and airflow limitation.
Explanation: ***Hyperinflated lungs and loss of lung markings*** - The patient's symptoms (shortness of breath, cough with sputum, fatigue, wheezing, prolonged expiratory phase, cyanosis, and 40 pack-year smoking history) are highly suggestive of **severe COPD, particularly emphysema**. - **Emphysema** is characterized by the destruction of alveolar walls, leading to enlarged air spaces, **hyperinflation of the lungs**, and a **loss of normal lung markings** due to decreased vascularity. *Perihilar mass with unilateral hilar enlargement* - This finding is suspicious for a **bronchogenic carcinoma**, which is possible in a heavy smoker. - However, the overall clinical picture, including bilateral wheezing, prolonged expiration, and signs of chronic hypoxemia (cyanosis, edema from potential right heart failure), points more strongly to widespread obstructive lung disease rather than a localized mass as the primary radiologic finding. *Cardiomegaly and increased bronchial markings* - **Cardiomegaly** can be seen in heart failure, and while the patient has leg edema (suggesting right heart strain due to lung disease or independent heart failure), his primary respiratory symptoms are more indicative of obstructive lung disease. - **Increased bronchial markings** suggest bronchial wall thickening, which can be seen in chronic bronchitis or asthma, but does not fully capture the diffuse destructive changes of emphysema that better fit the clinical presentation. *Subpleural cystic enlargement* - **Subpleural cystic enlargement** can be seen in conditions like **pulmonary fibrosis** (e.g., usual interstitial pneumonia), which presents with restrictive lung disease. - This pattern is inconsistent with the patient's obstructive symptoms of wheezing and prolonged expiratory phase, which are characteristic of airflow limitation. *Calcified pleural plaques surrounding the diaphragm* - **Calcified pleural plaques** are a hallmark sign of **asbestos exposure**. - While possible given his age, there is no history of asbestos exposure, and these plaques are typically asymptomatic, not explaining the acute worsening of respiratory symptoms.
Explanation: ***Decreased serum Na+*** - **Hyponatremia** in heart failure is often due to increased **ADH secretion** and impaired free-water clearance, reflecting more advanced disease. - It is an independent predictor of increased **morbidity and mortality** in patients with heart failure due to its association with severe hemodynamic compromise and neurohumoral activation. *Decreased QRS complex duration* - A **decreased QRS duration** generally indicates more efficient ventricular depolarization, which is a positive sign and not associated with increased mortality in heart failure. - Prolonged QRS duration, often seen in **conduction abnormalities** like bundle branch blocks, is linked to worse outcomes. *Decreased BNP levels* - **Brain natriuretic peptide (BNP)** is a biomarker released in response to ventricular stretch and volume overload. - **Decreased BNP levels** would suggest less severe heart failure or effective treatment, correlating with improved outcomes, not increased mortality. *Increased heart rate variability* - **Increased heart rate variability (HRV)** indicates robust autonomic nervous system function and is generally associated with a healthy cardiovascular system. - In heart failure, **decreased HRV** is a common finding and is associated with increased mortality, reflecting impaired autonomic balance. *Increased VO2* - **VO2 max** (maximal oxygen consumption) is a measure of aerobic capacity and a strong predictor of prognosis in heart failure. - **Increased VO2 max** indicates better exercise tolerance and cardiovascular fitness, which is associated with better outcomes and decreased mortality, not increased mortality.
Explanation: ***Initiate dopamine therapy and diuresis*** - This patient is presenting with **cardiogenic shock** secondary to extensive NSTEMI, characterized by **hypotension**, signs of **end-organ hypoperfusion** (confusion, cool clammy skin), **pulmonary edema** (crackles, dyspnea, elevated jugular venous pressure), and **severely reduced ejection fraction**. Dopamine is a vasopressor that can increase cardiac output and blood pressure. - **Diuresis** with loop diuretics such as furosemide is crucial to reduce the fluid overload contributing to the pulmonary edema and jugular venous distention. *Obtain blood cultures and start preliminary broad-spectrum antibiotics* - While infection is a concern in critically ill patients, there are **no signs of infection** in this clinical presentation. The patient's symptoms are clearly attributable to acute cardiac decompensation. - A delay in treating cardiogenic shock to investigate for infection would be detrimental and potentially fatal. *Start intravenous fluids and epinephrine therapy* - Intravenous fluids would **worsen the existing pulmonary edema and fluid overload** in a patient with an ejection fraction of 20% and clinical signs of volume overload (crackles, JVD, S3 gallop). - Epinephrine is a potent vasopressor but is generally reserved for more severe shock refractory to other inotropes, or in cases of **cardiac arrest**, not typically first-line for cardiogenic shock with significant pulmonary congestion. *Intubate the patient and perform an emergency cardiocentesis* - While the patient is confused and has respiratory distress, **intubation** should be considered after hemodynamic stabilization, if respiratory failure persists or worsens. - **Cardiocentesis** is indicated for **cardiac tamponade**, which is not supported by the absence of an effusion on bedside sonography and the finding of hypodynamic anterior wall movement, which points to pump failure. *Insert two large-bore intravenous catheters and start rapid fluid resuscitation* - This patient is in **cardiogenic shock with clear evidence of fluid overload**, including pulmonary edema and elevated jugular venous pressure. - **Rapid fluid resuscitation would exacerbate heart failure** and worsen respiratory compromise due to increased preload.
Explanation: ***Refer the patient to a dietician*** - The patient has **non-compliance with both diet and medication**, along with significant weight gain (5 kg) and severely uncontrolled diabetes (HbA1c 9.8%). A dietician can provide structured education on **nutrition management**, help address barriers to lifestyle adherence, and support weight management. - Dietician referral is a **concrete, actionable intervention** that directly addresses multiple issues: the stated diet non-compliance, weight gain, and provides diabetes self-management education that can improve overall medication adherence. - This intervention provides **professional support** beyond what can be achieved in brief physician visits and is appropriate before escalating to more complex medication regimens. *Schedule more frequent follow-up visits* - While increased monitoring may seem reasonable, this is a **passive approach** that doesn't provide the patient with concrete tools or resources to address her diet non-compliance and weight gain. - With an HbA1c of 9.8%, simply watching and waiting with more frequent visits is insufficient; **active intervention** is needed to address the underlying behavioral and lifestyle issues. - More frequent visits alone don't provide the structured education and support this patient needs. *Add glyburide to the medication regimen* - Adding a **sulfonylurea** like glyburide would likely worsen the patient's weight gain, as these drugs stimulate insulin release and commonly cause weight gain of 2-3 kg. - Before adding medications, addressing the **underlying adherence issues** with current therapy is more appropriate, as medication intensification in a non-adherent patient is unlikely to be effective. - Glyburide also carries a higher risk of **hypoglycemia** compared to metformin. *Stop metformin and begin an insulin regimen* - Starting insulin without first addressing **medication adherence** and lifestyle factors is premature, especially when the patient is already struggling with a simpler oral medication regimen. - Insulin initiation requires intensive patient education, frequent glucose monitoring, and excellent self-management skills, making it particularly challenging for a patient with documented **adherence difficulties**. - Before escalating to insulin, interventions targeting diet, lifestyle, and adherence should be attempted. *Refer the patient to an endocrinologist* - Endocrinology referral is typically reserved for **complex diabetes cases** with multiple complications, failure of optimal primary care management, or need for advanced therapies. - The primary issue here is **non-compliance with basic management**, which can and should be addressed in primary care with appropriate support services (dietician, diabetes educator). - Referral to an endocrinologist doesn't address the fundamental adherence and lifestyle issues this patient faces.
Explanation: ***Correct: Echocardiography*** - The patient's history of **STEMI 9 months ago**, **dyspnea on exertion**, **bilateral pitting lower extremity edema** that worsens in the evening, **dubious S3 gallop**, and **hepatomegaly** are classic findings of **heart failure post-myocardial infarction**. - **Echocardiography** is the **gold standard test** to assess **left ventricular function**, **ejection fraction**, **regional wall motion abnormalities**, and **valve function**, which are crucial for diagnosing and determining the severity of heart failure post-MI. - This test will directly reveal the cardiac cause of the patient's symptoms and guide management decisions. *Incorrect: D-dimer measurement* - This test is primarily used to rule out **deep vein thrombosis (DVT)** or **pulmonary embolism (PE)**, neither of which is strongly suggested by the patient's bilateral, gradual-onset edema and cardiac symptoms. - A negative D-dimer is useful to exclude DVT/PE, but a positive result is non-specific and would not explain the other cardiac findings like dyspnea on exertion, S3 gallop, and hepatomegaly. *Incorrect: Doppler color ultrasound of the lower extremity* - This imaging is used to evaluate for **venous insufficiency** or **deep vein thrombosis**, which typically cause unilateral or acute edema with skin changes. - While chronic venous insufficiency could cause bilateral edema, the presence of **dyspnea on exertion**, **S3 gallop**, and **hepatomegaly** strongly points to a **cardiac origin** rather than venous disease. *Incorrect: Soft tissue ultrasound of the lower extremities* - This test is used to evaluate for **localized soft tissue infection (cellulitis)**, **abscesses**, or other **structural abnormalities** in the subcutaneous tissue. - The patient's edema is described as **pale with no signs of lesions**, non-tender, and bilateral, making soft tissue pathology unlikely. Additionally, there are no signs of inflammation or infection. *Incorrect: T4 and thyroid-stimulating hormone assessment* - While **hypothyroidism** can cause edema (myxedema), it typically presents as **non-pitting edema** and is usually accompanied by other symptoms like fatigue, weight gain, cold intolerance, and bradycardia beyond what beta-blockers would cause. - The patient's symptoms with **pitting edema**, **post-MI history**, **dyspnea on exertion**, and **S3 gallop** are pathognomonic for cardiac causes, and there are no specific signs pointing to thyroid dysfunction.
Explanation: ***Captopril*** - The patient presents with classic symptoms of **heart failure** (shortness of breath at rest and with exertion, orthopnea, paroxysmal nocturnal dyspnea), a history of **myocardial infarction**, and a **reduced left ventricular ejection fraction (LVEF) of 33%**. - **ACE inhibitors** like captopril are first-line agents for heart failure with reduced ejection fraction (HFrEF) as they **improve survival**, reduce hospitalizations, and alleviate symptoms by decreasing **afterload** and **preload**, and preventing cardiac remodeling. *Levofloxacin* - This is an **antibiotic** used to treat bacterial infections. - While crackles can be present in pneumonia, the patient is **afebrile**, has no sick contacts, and the clinical picture, including orthopnea and paroxysmal nocturnal dyspnea, points strongly to **heart failure**, not infection. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** predominantly used for rate control in arrhythmias or to treat hypertension and angina. - It has a negative **inotropic effect** and can **worsen heart failure** in patients with reduced ejection fraction, making it contraindicated in this case. *Niacin* - **Niacin** is used to lower **LDL cholesterol** and raise **HDL cholesterol**, often for dyslipidemia. - While the patient has a history of hyperlipidemia, his acute symptoms and low ejection fraction indicate a need for **heart failure treatment**, not additional lipid management. *Nitroglycerin* - **Nitroglycerin** is a **vasodilator** primarily used for **angina** or in acute heart failure to reduce preload and afterload. - While it might provide temporary symptomatic relief in acute decompensated heart failure, it's not a long-term foundational therapy like ACE inhibitors for **chronic HFrEF** to improve survival and prevent progression.
Explanation: ***Hemosiderin-laden macrophages*** - The patient's history of **antiphospholipid syndrome** and symptoms of **shortness of breath**, **chest pain**, and **jugular venous distention** suggest **pulmonary hypertension**. - **Right heart catheterization** results (**mean pulmonary arterial pressure 30 mm Hg**, **pulmonary capillary wedge pressure 10 mm Hg**) confirm **pulmonary arterial hypertension (PAH)**, which, in the context of antiphospholipid syndrome, strongly indicates **chronic thromboembolic pulmonary hypertension (CTEPH)**. **Hemosiderin-laden macrophages** ("heart failure cells") are characteristic findings in the lungs of patients with chronic pulmonary congestion or recurrent pulmonary hemorrhage, which can occur in CTEPH due to the impact of chronic emboli on the pulmonary vasculature, leading to microhemorrhages and subsequent iron deposition. *Constriction of the renal afferent arteriole* - This is characteristic of conditions like **hypertensive nephrosclerosis** or involvement in systemic vasculitides, but it is not directly related to the primary pulmonary pathology described. - While patients with antiphospholipid syndrome can develop renal complications (e.g., microangiopathy), it is not the most likely finding explained by the pulmonary symptoms and hemodynamic measurements. *Mitral valve leaflet thickening* - **Mitral valve leaflet thickening** and stenosis would lead to an **elevated pulmonary capillary wedge pressure (PCWP)**, indicating **post-capillary pulmonary hypertension**. - The patient's PCWP is 10 mm Hg, which is within the normal range, ruling out significant left-sided heart disease as the primary cause of her pulmonary hypertension. *Dilation of the coronary sinus* - **Dilation of the coronary sinus** typically occurs due to conditions causing **elevated right atrial pressure** or **shunting from the left side of the heart**, such as an unroofed coronary sinus or persistent left superior vena cava. - While right heart pressures are elevated, this finding is not a direct or specific consequence of the suspected CTEPH. *Decreased left ventricular contractility* - **Decreased left ventricular contractility** would lead to **elevated left ventricular end-diastolic pressure** and, consequently, an **elevated pulmonary capillary wedge pressure**. - The normal PCWP of 10 mm Hg rules out significant left ventricular systolic dysfunction as the cause of the patient's pulmonary hypertension.
Explanation: ***High-output heart failure*** - The patient's symptoms of **dyspnea, orthopnea, pitting edema, jugular venous distention, crackles**, and **S3 gallop** strongly indicate **heart failure**. The **bounding pulse** and **wide pulse pressure** (systolic 106, diastolic 58) in the presence of an **arteriovenous fistula** suggest a **high-output state**. - An **arteriovenous fistula** used for hemodialysis can significantly increase **cardiac preload** and reduce **afterload**, leading to a persistent increase in **cardiac output**. Over time, this chronic increase in demand can overwhelm the heart, resulting in **high-output heart failure**. *AV fistula aneurysm* - An **AV fistula aneurysm** is a localized dilatation of the fistula and would typically present as a painful or compressible mass. - While it's a complication of AV fistulas, it does not directly explain the systemic signs of **heart failure** observed in this patient. *Pulmonary embolism* - **Pulmonary embolism** typically presents with sudden onset **dyspnea, pleuritic chest pain**, and sometimes **tachycardia** and **hypoxia**. - This patient's symptoms are of gradual onset, accompanied by clear signs of **fluid overload** and **cardiac dysfunction** like an S3 gallop, which are not typical for a PE. *Constrictive pericarditis* - **Constrictive pericarditis** causes symptoms of **right-sided heart failure** due to impaired diastolic filling, often with a **pericardial knock** and **Kussmaul's sign**. - While it can manifest with pedal edema and JVD, the **S3 gallop** and especially the **bounding pulse** and **wide pulse pressure** are inconsistent with constrictive pericarditis, which would typically cause a low-output state. *Dialysis disequilibrium syndrome* - **Dialysis disequilibrium syndrome** occurs shortly after hemodialysis, usually during or immediately after the first few sessions. It is characterized by neurological symptoms such as **headache, nausea, vomiting, confusion**, and **seizures**. - The patient's symptoms have been evolving over a month and describe a state of **fluid overload** and **cardiac dysfunction**, not acute neurological symptoms related to dialysis.
Explanation: ***Ventricular hypertrophy with sarcomeres duplicated in parallel*** - This patient presents with symptoms and signs consistent with **diastolic heart failure** due to **hypertension**, including exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, S4 gallop, and preserved ejection fraction on echocardiogram. - **Chronic hypertension** causes increased **afterload**, leading to **concentric left ventricular hypertrophy** where new sarcomeres are added in **parallel**, thickening the ventricular wall, and contributing to impaired relaxation and diastolic dysfunction. *Macrophages with hemosiderin* - **Hemosiderin-laden macrophages ("heart failure cells")** are typically found in the **lungs** in cases of chronic **pulmonary congestion** due to **left-sided heart failure**. - While pulmonary congestion is present, this option describes a finding in the **lungs**, not the specific myocardial change causing the heart failure. *Asymmetric hypertrophy of the interventricular septum* - This is a hallmark feature of **hypertrophic cardiomyopathy (HCM)**, an inherited genetic disorder, often causing **dynamic left ventricular outflow tract obstruction**. - There are no other features suggestive of HCM in this patient; her symptoms are more consistent with **hypertensive heart disease**. *Ventricular hypertrophy with sarcomeres duplicated in series* - Duplication of sarcomeres **in series** leads to **eccentric hypertrophy**, which is typically seen in conditions of **volume overload**, such as **dilated cardiomyopathy** or **aortic regurgitation**. - This patient's presentation with **preserved ejection fraction** and chronic hypertension points towards **pressure overload** and concentric hypertrophy, not eccentric hypertrophy. *Granuloma consisting of lymphocytes, plasma cells and macrophages surrounding necrotic* - This description is characteristic of a **granuloma** seen in conditions like **tuberculosis** or **cardiac sarcoidosis**, the latter of which can cause restrictive cardiomyopathy. - While sarcoidosis can cause heart failure, the patient's long-standing **hypertension** is a much more common and direct cause of her reported symptoms and findings.
Explanation: ***Decreased diffusing capacity of the lungs for carbon monoxide (DLCO)*** - This patient's presentation with **progressive dyspnea**, **chronic cough**, **wheezing**, **25 pack-year smoking history**, and **chronic respiratory acidosis with metabolic compensation** (elevated PCO2 48, elevated HCO3- 32) is highly suggestive of **COPD with emphysema component**. - The **ABG pattern shows chronic CO2 retention** with renal compensation (elevated bicarbonate), which is characteristic of **chronic obstructive lung disease**, not restrictive disease. - In **emphysema**, there is **destruction of alveolar walls** and loss of elastic recoil, leading to **impaired gas exchange** and **decreased DLCO** due to reduced surface area for gas diffusion. - Decreased DLCO is a hallmark finding in emphysema and helps differentiate it from chronic bronchitis (where DLCO may be normal). *Incorrect: Shift of the flow volume loop to the right* - While this patient likely has **obstructive lung disease (COPD)**, a shift of the flow-volume loop to the **right** indicates **increased lung volumes and hyperinflation**, not the loop shape itself. - In COPD, the flow-volume loop shows **decreased flow rates** (scooped appearance) rather than a simple rightward shift, making this description imprecise. *Incorrect: Decreased lung compliance* - **Decreased lung compliance** is characteristic of **restrictive lung diseases** (e.g., pulmonary fibrosis, ARDS) where lungs become stiff. - In **emphysema/COPD**, lung compliance is typically **increased** (lungs become more compliant/floppy) due to loss of elastic tissue, not decreased. - This patient's ABG pattern of chronic hypercapnia indicates obstructive disease, not restrictive disease. *Incorrect: Decreased lung residual volume* - This is the **opposite** of what would be expected in COPD/emphysema. - In **obstructive lung disease**, residual volume is **increased** due to **air trapping** and inability to fully exhale. - **Decreased residual volume** would be seen in **restrictive lung diseases**, which does not fit this patient's chronic hypercapnic respiratory acidosis. *Incorrect: Increased FEV1/FVC ratio* - This is the **opposite** of what would be expected in COPD. - In **obstructive lung disease**, the FEV1/FVC ratio is **decreased** (typically <0.70) because airflow limitation reduces FEV1 more than FVC. - An **increased FEV1/FVC ratio** is seen in **restrictive lung diseases**, where both volumes decrease but FVC decreases proportionally more than FEV1.
Explanation: ***IV NS*** - The patient presents with **hypotension (85/55 mmHg)** and **tachycardia (130 bpm)**, indicating significant **volume depletion** despite a history of congestive heart failure. - **Isotonic intravenous fluids (e.g., normal saline)** are crucial in the initial management of **diabetic ketoacidosis (DKA)** or **hyperosmolar hyperglycemic state (HHS)** to restore intravascular volume and improve tissue perfusion. *IV ½ NS* - **Hypotonic solutions** such as IV ½ NS are typically used later in DKA/HHS management, once the patient's **hemodynamic stability** has been achieved and serum sodium levels are stable or elevated. - Administering hypotonic fluids to an already **hypotensive and volume-depleted patient** could worsen hypotension and potentially lead to cerebral edema if not carefully monitored. *IV insulin* - While insulin is essential for correcting hyperglycemia, it is administered **after or concurrently with fluid resuscitation** to avoid worsening hypovolemia as it drives glucose and potassium into cells, potentially causing **hypokalemia** and further **hemoconcentration**. - **Fluid resuscitation** should always precede or be initiated simultaneously with insulin therapy, especially in cases of hemodynamic instability. *Subcutaneous insulin injection* - **Subcutaneous insulin** is not appropriate for initial management in this critically ill patient due to its **slower onset of action** and potentially **erratic absorption** in hypotensive and poorly perfused states. - **Intravenous insulin** is preferred in DKA/HHS for its rapid, titratable effect. *IV D5W* - **Dextrose 5% in water (D5W)** is a hypotonic solution primarily used when **blood glucose levels fall below 250 mg/dL** during DKA/HHS treatment to prevent hypoglycemia. - Administering D5W in a patient with a **serum glucose of 500 mg/dL** would further elevate blood sugar and worsen the hyperosmolar state.
Explanation: ***Progressive obstruction of expiratory airflow*** - This patient's **40-year smoking history** strongly suggests **Chronic Obstructive Pulmonary Disease (COPD)**, characterized by **progressive airflow limitation** that is not fully reversible. - Symptoms like **chronic cough with white phlegm**, **dyspnea on exertion** (walking up stairs), and **wheezing/rhonchi** are classic findings in COPD, which involves obstruction of expiratory airflow. *Chronic decrease in pulmonary compliance* - **Decreased pulmonary compliance** is characteristic of **restrictive lung diseases**, such as **pulmonary fibrosis**, where the lungs become stiff and difficult to expand. - This patient's symptoms and smoking history are more consistent with an obstructive process, not a restrictive one. *Local accumulation of kinins* - **Kinins** are inflammatory mediators associated with conditions like **angioedema** or **acute inflammation**, causing pain, swelling, and vasodilation. - While inflammation plays a role in COPD, kinin accumulation is not the primary underlying cause of the chronic symptoms described. *Mycobacterial invasion of pulmonary parenchyma* - **Mycobacterial invasion** implies **tuberculosis**, which typically presents with fever, night sweats, weight loss, and a more persistent, often bloody cough. - The patient's chronic, productive cough of white phlegm and lack of systemic symptoms like fever make tuberculosis less likely. *Incremental loss of functional residual capacity* - **Loss of functional residual capacity (FRC)** typically occurs in **restrictive lung diseases** where lung volumes are reduced due to decreased compliance. - In COPD, FRC tends to be **increased** due to **air trapping** and hyperinflation, rather than decreased.
Classification of heart failure (HFrEF vs HFpEF)
Practice Questions
Heart failure pathophysiology
Practice Questions
Acute decompensated heart failure
Practice Questions
Chronic heart failure management
Practice Questions
Guideline-directed medical therapy
Practice Questions
Device therapy for heart failure
Practice Questions
Cardiomyopathies
Practice Questions
Valvular heart disease and heart failure
Practice Questions
Right heart failure
Practice Questions
Pulmonary hypertension
Practice Questions
Cardio-renal syndrome
Practice Questions
Advanced heart failure and transplantation
Practice Questions
Quality measures in heart failure
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free